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Abstract 
Myocardial infarction is the largest cause of morbidity and mortality worldwide. 
Despite optimal treatment, patients have a mortality which approaches 12% at 
six months. 
Reperfusion of the ischaemic myocardium is essential to salvage 
myocardium. However, reperfusion itself is harmful, with up to 40% of 
myocardial necrosis occurring at this time. This is known as “Lethal 
Reperfusion Injury”. Opening of the mitochondrial permeability transition pore 
(MPTP), a channel situated in the inner mitochondrial membrane is central to 
this process. In its quiescent state, the MPTP remains closed, but once open 
it becomes non-selectively permeable to solutes of up to 1.5 kDa, resulting in 
rapidly advancing necrotic cell death.  
The molecular structure of the MPTP has not yet been fully determined, 
although cyclophilin D (Cyp D) has been shown to be essential to its function. 
Genetic ablation of Cyp D has been shown to result in delayed opening of the 
MPTP and resistance to myocardial damage after acute ischaemia-
reperfusion injury. MPTP inhibition is cardioprotective, and may be achieved 
by a variety of means including ischaemic pre- and post-conditioning, and by 
pharmacological agents.  
The aim of this thesis is to investigate the role of the MPTP (cyclophilin D) in 
cardioprotection from acute ischaemia-reperfusion injury. 
In chapter 4 we investigate whether it is possible to protect the heart in mice 
deficient of cyclophilin D by applying a stronger ischaemic preconditioning 
stimulus to that previously investigated in vivo. We found that there was a 
Cara Hendry 
 
4 
non-statistically significant trend towards a protective effect in cyclophilin D 
deficient mice which were subjected to a stronger IPC stimulus than that 
previously studied in vivo.  
Chapter 5 explores whether it is possible to protect the heart whilst avoiding 
the deleterious extra-cardiac effects of cyclosporin A by sub-cellular targeting 
of cyclosporin A (CsA) to mitochondria in the first in vivo testing of a 
mitochondrial-specific form of CsA (mtCsA). We demonstrated that mtCsA 
administered at reperfusion did not protect the heart of wild type mice from 
ischaemia- reperfusion. 
Chapter 6 examines the possibility of achieving cardioprotection independent 
of cyclophilin D. In this chapter, the effects of the matrix metalloproteinase 
inhibitor, Ilomastat, are studied. We confirmed that MMP inhibition was 
cardioprotective in wild type mice and also showed for the first time in vivo 
that administration of ilomastat can protect the heart from ischaemia- 
reperfusion in mice deficient in cyclophilin D. 
In summary our data supports the hypothesis that it is possible to protect the 
heart from ischaemia – reperfusion in cyclophilin D deficiency by 
administration of an MMP inhibitor at reperfusion. We also showed a trend 
towards cardioprotection in cyclophilin D deficiency by administration of an 
increased IPC stimulus. Together, these data may suggest that necrotic cell 
death may not all be mediated by the MPTP, or possibly, that the MPTP may 
exhibit a threshold effect which is surmountable by an increase in inhibitory 
action of combined pharmacology or increase in IPC stimulus. 
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Chapter 1-Introduction 
1.1 Epidemiology of Acute Myocardial Infarction 
Ischaemic heart disease (IHD) is the leading cause of morbidity and mortality 
worldwide (1). It has previously been demonstrated that after coronary 
occlusion occurs, survival is directly related to the extent of cardiac muscle 
loss (2). The most important factor in salvaging myocardium is the restoration 
of flow to the affected coronary artery territory (reperfusion) (3-5). This may be 
achieved by mechanical (primary percutaneous coronary intervention) or 
pharmacological means (thrombolysis). The principal determinant of infarct 
size is the duration of ischaemia (6,7) and thus one of the major targets of 
treatment of myocardial infarction is to reduce the time to reperfusion after the 
onset of arterial occlusion. However, there is a “ceiling” effect in terms of 
reducing time to reperfusion: progress may be limited by a variety of factors 
which may be strategic (ie related to transport and treatment delays) or patient 
related (delay in symptom recognition before the call to help). Inevitably, even 
despite optimal treatment, some degree of cardiac damage does occur and 
the six month mortality rate of up to 12% reflects this (8). This high mortality 
rate is the driver behind the search to find interventions which may reduce 
infarct size further. In investigating this, it is important to understand the 
pathological processes involved in the myocardial cell death which occurs in 
the reperfused acute myocardial infarction. 
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1.2 Physiological changes in Acute Myocardial Infarction 
Acute myocardial infarction is caused by the rupture of an atherosclerotic 
plaque, subsequent platelet activation and formation of occlusive thrombus in 
the affected coronary artery. This in turn results in cessation of delivery of 
oxygenated blood to the myocardium and the tissue becomes ischaemic.  
However the extent of cellular necrosis is not fully determined during the 
period of index ischaemia in the reperfused myocardium. Jennings in 1960 
(9), first reported the pathological changes which take place after reperfusion 
of the circumflex artery in a canine model, describing what later became 
known as “lethal reperfusion injury”.  
Although opening the occluded artery is essential to salvaging viable 
myocardium, the process of reperfusion itself leads to a variety of changes 
which take place at the cellular level which are deleterious to the myocardium. 
In fact, reperfusion itself accelerates the process of myocardial necrosis. This 
has been debated in the literature (10) - but the finding that interventions 
given at the time of reperfusion can reduce infarct size by up to 40%) (11-15), 
supports the theory that reperfusion itself creates a degree of myocardial 
damage, with the clear implication that tissue is “salvageable” during this time. 
This rapid process of cardiac damage is referred to as “Lethal Reperfusion 
Injury” (LRI), and it is defined as “injury caused by restoration of blood flow 
after an ischaemic episode leading to death of cells which were only reversibly 
injured during the preceding ischaemic episode”(16).  
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1.3 The Effect of Ischaemia on the Myocardium 
To fully understand lethal reperfusion injury, it is imperative to appreciate the 
effect of ischaemia itself on the myocardium.  
The cessation of antegrade coronary flow results in a variety of changes at the 
cellular level- as a result of tissue hypoxia (due to lack of delivery of 
oxygenated blood) and failure of the nutrient (adenosine triphosphate (ATP) 
supply. The immediate effect of tissue hypoxia is failure of oxidative 
phosphorylation, with resultant failure of aerobic synthesis of ATP. Adenosine 
diphosphate (ADP), inorganic phosphate and reduced cofactors and 
coenzymes (eg NADH) then accumulate. Metabolism then switches to 
anaerobic glycolysis. This results in acidosis, both from lactate production and 
generation of hydrogen ions. The overall result is a rise in intracellular 
potassium and sodium and over-riding acidosis due to lactate production, 
reduced CO2 efflux, and failure of the ATP driven H
+ pumps (17). 
If the ischaemic insult persists beyond a critical duration, then the damage 
sustained becomes irreversible. This does not happen uniformly within the 
myocardium, but is incremental throughout the period of ischaemia beginning 
in the subendocardium and progressing to the epicardium (7). This was first 
described by Reimer and Jennings and this phenomenon is known as the 
“wavefront of cell death”.  
The processes resulting in this cell death are described in brief overleaf.  
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The hallmark of irreversible damage is the loss of membrane integrity. This is 
the result of increased intra-cellular osmolarity creating an osmotic gradient, 
drawing water into the cell and causing it to become oedematous.  
The cytosolic calcium concentration also rises during ischaemia. The 
sarcoplasmic reticulum cannot take up this redistributed calcium as there is 
inadequate phosphorylation of ATP. This results in increased calcium release 
further exacerbating the problem. 
During ischaemia toxic lipid metabolites accumulate – eg acetyl- CoA, acyl 
CoA. Activation of phospholipase A2 causes breakdown of the phospholipid 
membrane and release of harmful free fatty acids some of which exert a direct 
toxic effect (18). Free fatty acids also promote generation of reactive oxygen 
species (ROS), by uncoupling oxidative phosphorylation. 
Reactive oxygen species (ROS) are a group of compounds which, as their 
collective title suggests are a group of highly reactive oxygen derived free 
radicals or free radical precursors. If the production of reactive oxygen species 
exceed the capacity of cellular scavengers to remove them oxidative stress 
results. This has a direct toxic effect on the cell (19). 
Cara Hendry 
 
23 
1.4 Lethal Reperfusion Injury 
 
At the time of reperfusion there is a dramatic and rapid alteration in the 
cellular physiology. These changes are complex, and involve interaction of a 
number of harmful processes.  
1.4.1 Restoration of physiological pH 
Firstly, there is a rapid restoration of physiological pH. This occurs because 
lactate is washed out of the cell, and there is activation of the Na/HCO3 
symporter and Na/H exchange (20). The rise in pH which occurs is 
cardiotoxic, causing opening of the MPTP, hypercontracture of the cell and 
cell death (20). Studies have shown that perfusion of post-ischaemic hearts 
with acidic buffer reduces myocardial damage (22) in animal models, but this 
has not been borne out in clinical trials of eniporide, an Na+/H+ exchange 
inhibitor given at reperfusion in the setting of acute myocardial infarction (23). 
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1.4.2 ROS generation 
Reoxygenation after an ischaemic insult to the myocardium has been shown 
to be directly harmful (24). It causes a degree of injury which is greater than 
the injury caused by ischaemia alone, and this has been referred to as “the 
oxygen paradox” (11,25,26). The mechanism for this is thought to be damage 
to mitochondria, which prohibits efficient transfer of electrons by complexes I 
and III of the electron transport chain, generating a huge burst of 
mitochondrial derived ROS, causing oxidative stress and resultant myocardial 
damage (27,28). 
An additional effect of oxidative stress is that it limits availability of nitric oxide 
which itself has a cardioprotective effect (11). 
Although it would appear that the role of ROS in myocardial damage seems 
undisputed, the literature is conflicted. There are several studies which appear 
to show benefit from treatment with ROS scavengers (29-31). In contrast, 
there are also a number of studies which appear to refute this (32,33). 
It is clear that ROS have been shown to stimulate opening of the MPTP (34), 
and thus are likely to play some role in lethal reperfusion injury, but 
pharmacological modulation of this in humans is difficult due to the very short 
therapeutic window required to achieve a useful clinical effect and the inability 
to achieve sufficient levels of the antioxidant in the cardiomyocyte. 
1.4.3 Rise in intracellular calcium 
The accumulation of intracellular calcium which begins during ischaemia is 
further exacerbated by reperfusion. During ischaemia, anaerobic metabolism 
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is the source of ATP synthesis, and this produces lactate, acidifying the 
cytosol. In order to try to maintain physiological pH, the sarcolemmal Na+/H+ 
exchange mechanism is activated. The sodium ions are then exchanged for 
calcium ions by the Na+/ Ca2+ exchanger (35). At the time of reperfusion, there 
is a rapid escalation in intracellular calcium content- this is due to damage to 
the sarcolemmal membrane and also dysfunction of the sarcoplasmic 
reticulum (11). A maladaptive response then occurs, whereby the calcium is 
taken up by the mitochondrial Ca2+ uniporter, driving calcium into the 
mitochondrial matrix (36). This, in turn, stimulates opening of the MPTP.  
 
1.4.4 Rise in inorganic phosphates (Pi) 
During the injurious ischaemic episode, inorganic phosphates accumulate 
within the mitochondrion. This is largely caused by a drop in the mitochondrial 
pH level, which leads inorganic phosphate to be taken up into mitochondria. 
This is a potent MPTP stimulant (202). 
 
1.5 The Mitochondrial Permeability Transition Pore 
1.5.1 What is the MPTP? 
The mitochondrial permeability pore (MPTP) is a non-specific channel located 
in the inner mitochondrial membrane, which was first discovered by Hunter 
and Haworth in the 1970s (37-39). Its critical involvement in tissue damage 
occurring during myocardial ischaemia / reperfusion was revealed in the 
1980s by Crompton (40-42). Under physiological conditions the pore remains 
closed. During ischaemia, due to inhibition by cellular acidosis, it remains 
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quiescent (43,44). The pore is sensitive to a number of stimuli as discussed 
above- alterations in calcium concentration, generation of reactive oxygen 
species, restoration of physiological pH and the presence of inorganic 
phosphate (45), conditions which are created within a few moments of 
reperfusion. When the pore opens it becomes freely permeable to solutes of 
up to 1.5 kDa including protons (38,46). The crossing of protons results in a 
rapid dissipation of the electrical gradient across the membrane and 
uncoupling of oxidative phosphorylation (failure of ATP generation) and also 
leads to reversal of the proton-translocating ATPase causing hydrolysis of 
ATP leading to profound ATP depletion (47). If the pore remains open, this will 
lead to rapidly advancing cell death by necrosis. At the same time, as proteins 
are unable to cross the membrane, an osmotic gradient is also generated 
between the cytosol and matrix, which causes the mitochondria to swell, 
rupturing the outer mitochondrial membrane and releasing cytochrome C (48). 
Cytochrome C then associates with apoptosis inducing factor and caspase-9, 
which induces the release of caspase-3 and onset of apoptosis. The pro-
apoptotic members of the Bcl-2 (B-cell lymphoma-2) family are also 
upregulated and contribute to apoptotic cell death in this setting (223).  
Importantly, the MPTP remains closed during myocardial ischaemia and 
opens only during the first few minutes of reperfusion (44), making it an ideal 
target for therapeutic manipulation in the setting of myocardial infarction. 
1.5.2 Components of the MPTP 
Despite much research, the precise structure of the MPTP remains elusive. Its 
function was initially thought to be the result of the interaction between a 
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number of subunits: namely cyclophilin D (Cyp D), the voltage dependent 
anion channel (VDAC) and adenine nucleotide translocase (ANT). Genetic 
studies have revealed that VDAC and the ANT play a non-essential role in 
pore function. The role of each, and the evidence for their involvement 
is detailed below. 
1.5.2 Cyclophilin D 
Cyclophilins are a group of proteins whose function is to catalyse the cis-trans 
isomerisation of peptidyl-prolyl bonds- hence being referred to as PPIases 
(peptidylprolyl cis-trans isomerases). Cyclophilin D, the mitochondrial isoform, 
is an 18kDa protein, and is located in the mitochondrial matrix (49). Its role in 
function of the MPTP was discovered after administration of cyclosporin A 
was found to be a potent inhibitor of the MPTP (50). Its identification as a 
PPIase took place shortly afterwards, by Halestrap’s group, who observed 
that cyclosporin and its analogues inhibited a matrix peptidyl-prolyl cis-trans 
isomerase (PPIase) and subsequently purified it from rat livers, identifying it 
as cyclophilin D (51-53). Work by Baines confirmed that cyclophilin D was an 
essential component of the MPTP (13).  
Ablation of the mouse Ppif gene which encodes cyclophilin D has enabled 
further understanding of its role in ischaemia-reperfusion injury (IRI). 
Mitochondria isolated from mice deficient in this gene have been shown to be 
resistant to the harmful effects of noxious stimuli including calcium overload 
and oxidative stress induced cell death (13), both of which are known to 
promote opening of the MPTP. Baines group also confirmed that MPTP 
opening was delayed in Ppif null mice and that they were protected to some 
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degree from IRI, with a significant reduction in the extent of infarction in 
comparison to wild type controls (13,54). Treatment with agents known to 
inhibit cyclophilins – Debio-25 (55), sanglifehrin A (56) have also been shown 
to inhibit the MPTP to a similar degree as Ppif null animals (57). As cyclophilin 
D is the binding site responsible for reduction in infarct size seen after 
ischaemia-reperfusion, these mice exhibit smaller infarct sizes and do not 
exhibit a further reduction in infarct size after administration of cyclosporin A 
(12).  
1.5.3 Voltage Dependent Anion Channel (VDAC) 
The voltage dependent anion channel (otherwise known as porin) is located in 
the outer mitochondrial membrane of all eukaryotic organisms (58).  Mammals 
have three isoforms (VDAC- 1, 2 and 3). VDAC was formerly considered to be 
essential for function of the MPTP. In its closed state it is permeable to solutes 
of up to 1.5 kDa (as is the open MPTP), and when open it allows solutes of 
molecular weight of up to 5kDa to pass. However, if VDAC was an essential 
part of the MPTP it would be expected that closure of VDAC would result in 
closure of the MPTP, protecting the mitochondrion from calcium influx- but, as 
noted above the closed state of VDAC allows the same size of molecules to 
pass as the open MPTP. In fact the closed VDAC increases calcium influx into 
mitochondria, which would conversely result in MPTP opening (59).  Initial 
data suggested that use of VDAC inhibitors also inhibited MPTP action, but 
these inhibitors were relatively non-selective in their site of action (60). Further 
data, in isolated mitochondria from mice lacking VDAC -1 has shown normal 
MPTP function, with inhibition by CsA (61). Experimental data by Baines et al, 
has demonstrated that cardiac fibroblasts lacking all three isoforms continue 
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to display MPTP activity in response to calcium and oxidative stress. 
Additionally, administration of cyclosporin A abolished this activity (62), 
refuting the previous suggestion that VDAC was a necessary component of 
the MPTP. It is more likely that VDAC instead plays a role in targeting of 
protective proteins such as Akt and protein kinase C.  
1.5 4 Adenine Nucleotide Translocase 
The adenine nucleotide translocase (ANT) is a small protein (approximately 
300 amino acids long) which is located in the inner mitochondrial membrane. 
There are four isoforms of translocase, ANT-1and ANT-2, both of which are 
present in rodents, and ANT-3, which is present in humans  but not rodents 
(63), and ANT-4 which is found in murine germ cells (64). The function of the 
translocase is to shuttle ATP and ADP across the inner mitochondrial 
membrane. Clues to its involvement in the function of the MPTP are that ATP 
and ADP directly inhibit the MPTP, but other nucleotides such as AMP, GDP 
and GTP, which don’t pass via the ANT do not. The ANT has two 
conformations – C (cytosolic) and M (matrix). Bongkreic acid shifts the ANT to 
the M conformation, whilst atractyloside shifts it to the C conformation. 
Bongkreic acid has been shown to block the calcium induced MPTP (52), 
whilst atractyloside sensitises the MPTP response to calcium (65) in isolated 
mitochondria. This would be in keeping with a change in conformation of the 
ANT, from its resting state into the pore-forming cytosolic type at the time of 
reperfusion. In further support of this, studies in isolated cardiomyocytes have 
shown that bongkreic acid protects against oxidative stress (66), and 
atractyloside blocks the protective effect of nitric oxide donors (67). 
Additionally, ANT-1 interacts with cyclophilin D at contact sites between the 
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inner and outer mitochondrial membranes- this is where the pore is thought to 
be located (68), implicating ANT-1 in MPTP function.   
Despite the evidence supporting its involvement in the MPTP, ANT is not 
thought to be an essential component. The fact that ANT-1, but not ANT-2 
interacts with cyclophilin is one of the arguments against it being an essential 
component: the MPTP is found in most organs, yet ANT-1 is only found in 
striated muscle. Knock out studies have also drawn the exact role of ANT in 
pore function into question. Mice with both ANT-1 and ANT-2 knocked out (ie -
/-) exhibit a typical pattern of calcium dependent pore action, and cyclosporin 
inhibits this (69). The calcium threshold for pore opening in the double knock-
out was elevated, which does suggest some degree of ANT involvement, but 
this data demonstrates conclusively that the ANT does not play an essential 
role in function of the MPTP. It is, however, considered to play a regulatory 
role in pore function. 
1.5.5 The mitochondrial phosphate carrier 
Recent data has suggested that the mitochondrial phosphate carrier may 
regulate MPTP opening although the data is far from conclusive. 
Data presented by Leung et al, shows that the phosphate carrier binds to 
cyclophilin D in a cyclosporin sensitive manner, and is also associated with 
the ANT, features which are suggestive of involvement in pore function (70). 
Its role has not yet been clearly established in pore function. 
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Figure 1.1 Schematic diagram of proposed structure of the MPTP 
 
1.6 Biological function of the MPTP 
The precise biological function of the MPTP remains unclear. Although 
genetic knock out studies initially suggested that loss of cyclophilin D exerts a 
positive effect on the myocardium, by protecting against ischaemia-
reperfusion injury, data is emerging which suggests that genetic ablation of 
CypD has a long-term maladaptive effect. Elrod et al presented a study which 
explored the role of cyclophilin D in the heart, and found that animals deficient 
in cyclophilin D were unable to increase myocardial contractility in comparison 
to wild type controls after administration of the β-adrenergic agonist 
isoproterenol. After exposure to trans- aortic constriction (TAC), the CypD 
deficient animals developed severe left ventricular hypertrophy and cardiac 
fibrosis, with animals of this genotype showing increased propensity to 
develop heart failure when faced with mechanical pressure overload. This was 
also found when exercise in the form of swimming was used to assess the 
effect of physiological (exercise induced) hypertrophy – the CypD -/- genotype 
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had a significantly higher mortality from drowning due to fatigue. Histology 
showed a greater degree of hypertrophy and pulmonary oedema than their 
wild type counterparts. Further investigations showed that cardiac 
mitochondrial calcium content was elevated in mice deficient of cyclophilin D, 
and that there was an increase in the calcium threshold for MPTP opening. 
Cyclosporin A was seen to increase calcium efflux from mitochondria. Altered 
substrate utilisation was also noted, with increased levels of dehydrogenase 
activity with a net result of increased glucose in this series of experiments 
(71). Elrod’s paper thus provides an important insight into the potential role of 
the MPTP in regulation of calcium metabolism and response to 
haemodynamic stress.  
The MPTP does appear to have more than one role, however, mediating 
necrotic cell death after reperfusion of an ischaemic organ, and also in 
mediating protection by preconditioning and postconditioning .  
The protection conferred by ischaemic preconditioning (discussed later in this 
chapter) is related to opening of the MPTP. In contrast to lethal reperfusion 
injury, IPC may be mediated by a transient opening of the MPTP, whereas in 
necrotic cell death, this is prolonged. This transient MPTP opening has been 
shown to be an essential part of IPC induced cardioprotection (72).  
Administration of MPTP blocking agents during preconditioning completely 
abolishes any protective effect. This effect is thought to result from 
mitochondrial uncoupling and subsequent reduction in calcium loading of 
mitochondria and increased mitochondrial ROS signalling (72).  
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1.7 Methods of cardioprotection:  MPTP Inhibition 
Infarct size is the strongest determinant of prognosis after acute myocardial 
infarction, and thus a wealth of research has been focussed on interventions 
to reduce infarct size. There is a degree of myocardial necrosis which is 
determined by the duration of ischaemia, but at the time of reperfusion, a 
substantial amount of damage occurs in tissue, which until then was 
salvageable - lethal reperfusion injury. The MPTP plays a major role in this 
cell death, and therefore interventions which inhibit its function have been the 
focus of much research. 
Cardioprotective strategies such as ischaemic preconditioning (15,73) and 
postconditioning (74) (discussed in more detail below) have been shown to 
inhibit opening of the MPTP, and reduce cell death after ischaemia-
reperfusion. In addition to this, drugs which inhibit MPTP function (75) have 
also been studied in detail and these are also discussed below. 
1.8 Mechanical methods of cardioprotection 
1.8.1 Ischaemic Preconditioning (IPC) 
Ischaemic preconditioning is a phenomenon whereby the application of a 
period of non-lethal ischaemia to an organ prior to a sustained injurious 
ischaemic insult results in protection from necrotic cell death (76). 
Murry et al in 1986 first reported in a canine model that brief periods of 
sublethal ischaemia administered to the circumflex artery before the onset of a 
prolonged ischaemic insult to the same vessel could protect against 
myocardial damage measured at four days post-reperfusion (76). These 
findings have been supported subsequently by a number of confirmatory 
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studies in a variety of animal models (54,77). Human cellular work using IPC 
in isolated cardiomyocytes (78) and superfused human myocardium (79) has 
also been successful in reducing cellular damage after an ischaemic insult.  
There appear to be two periods during which the heart is maintained in a 
“preconditioned” state- the initial period, within 1-2 hours of the 
preconditioning stimulus (80), and a later “second window” of protection 
(SWOP), where the cardioprotective effect has been shown to recur 24 hours 
later and last for 2-3 days- described by some researchers as “delayed” or 
“late” IPC. 
The mechanisms involved in IPC still remain elusive despite much research, 
but the signalling mechanisms involved are being discovered slowly over time.  
The IPC stimulus causes release of a series of autacoids (eg bradykinin (81), 
adenosine (82) and opioids (83)) from the organ being preconditioned. 
Blockade of any one of these agents abolishes the protective effect of IPC. 
These autacoids are all thought to act in parallel with one another and act via 
G- protein coupled receptors.  
More than one pathway for the protection of IPC has been proposed  
Inhibition of protein kinase C (PKC) has been shown to block the protective 
effect of all three substances (84-86), leading to the conclusion that PKC is a 
downstream point of convergence for the action of autacoids.  
The autacoids also act via G protein-coupled receptors to trigger activation of 
signal transduction pathways involving PI3K- Akt- e NOS, Erk 1 /2, p38, JNK 
MAPK, JAK-STAT3, PKC/PKG (the signalling kinases) which act on 
downstream effectors such as the mitochondrial potassium- ATP channel, 
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MPTP, and ROS. These are referred to as pro-survival kinases. These then 
inhibit the MPTP (87), by a mechanism which to date is currently unknown. 
 
Figure 1.2 Simplified diagram of pathway resulting in the protective effect of 
ischaemic preconditioning. 
 
Postconditioning achieves protection by similar means (87,88), and both pre- 
and postconditioning act via pathways which are convergent at the point of 
reperfusion- this is collectively referred to as the reperfusion injury salvage 
kinase (RISK) pathway (89). 
A further pathway has also been found – which is referred to as the survival 
activating factor enhancement (SAFE) pathway (90). This has been reported 
to involve TNF- α activation, Signal Transducer and Activator of Transcription 
3 (STAT3) and its actions are independent of the RISK pathway (91).  
 
At the time of reperfusion after a sustained ischaemic insult, the MPTP is 
known to open. This is a sustained “high-conductance” opening, and this 
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event is a critical mediator of lethal reperfusion injury. However, the MPTP 
can open transiently, (as in IPC) and this can affect calcium efflux and 
mitochondrial calcium load (92). It has also been shown that transient pore 
opening can mediate mitochondrial ROS release (93) and may be triggered by 
mitochondrial uncoupling (94). These findings prompted further study, by 
Hausenloy et al, in order to determine whether transient opening of the MPTP 
could be a primary mediator of the cardioprotection afforded by IPC. The 
findings of this study in a Langendorff model of ischaemia-reperfusion 
confirmed that the cardioprotection of IPC, diazoxide and mitochondrial 
uncoupling were dependent on both MPTP opening and reactive oxygen 
species (72). This placed the MPTP in a crucial role for both IPC and lethal 
reperfusion injury.   
This role has been confirmed in experimental data showing that administration 
of MPTP inhibitors during the IPC stimulus abolishes generation of 
mitochondrial ROS (95) and also cardioprotection (72). Additionally, mice 
deficient in cyclophilin D, an essential component of the MPTP do not appear 
to be protected after ischaemic preconditioning (54). Hausenloy et al 
confirmed that the protective effect of IPC was mediated by MPTP inhibition 
(15). 
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Figure 1.3 Simplified diagram of the role of transient MPTP opening as a 
mediator of the cardioprotection of IPC (reproduced with permission, 
Hausenloy et al (203) 
The benefit of IPC in reduction of cardiac damage after sustained ischaemia 
countered the previous widely held belief that infarct size was fully determined 
during ischaemia and held huge potentially beneficial implications for the 
reduction in cellular injury sustained during an ischaemic event.  
Although of great scientific importance, this data had one large drawback in 
terms of direct clinical application in treatment of acute myocardial infarction 
(AMI) –primarily because in the real world setting, the onset of myocardial 
infarction is usually unprecedented. However this method does have a 
potential role in situations where the onset of ischaemia is predictable- in 
vascular (96,97), gastro-intestinal (98), cardiac (99) and transplant surgery.   
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1.8.2 Ischaemic Postconditioning (IPOC) 
In 2003, Zhao demonstrated in a canine model of reperfused myocardial 
infarction (with the LAD as the target vessel) that the application of three brief 
periods of ischaemia – reperfusion as a postconditioning stimulus immediately 
after reperfusion resulted in a reduction in infarct size measured at three 
hours (100). This data was supported in a variety of models (101) and was 
welcomed, as it lent new promise to future therapy for STEMI. In fact, after 
investigation in small numbers of patients, the use of ischaemic 
postconditioning (by inflating an angioplasty balloon for brief periods after 
restoration of coronary flow) in the catheter laboratory has been subsequently 
shown to reduce markers of myocardial injury, such as release of creatinine 
kinase and improve angiographic markers of reperfusion (blush grade) (102). 
However, the introduction of thrombectomy (manual aspiration of thrombus 
during treatment of acute myocardial infarction by primary angioplasty), has 
made it difficult to perform and assess the effect of postconditioning in the 
setting of primary angioplasty. To date no study of postconditioning has 
demonstrated a reduction in mortality. In addition, recent data, using 
myocardial salvage index, left ventricular ejection fraction, and infarct size by 
MRI as the outcome measures has been disappointing- with no improvement 
in any of these measures after three cycles of postconditioning in the setting 
of acute myocardial infarction (204). However, there is data utilising surrogate 
outcome measures, such as troponin and creatinine kinase release which do 
show benefit. To date the clinical trials have all had small patient numbers. 
There are also other studies, which are currently underway, such as the 
Danish Study of Optimal Acute Treatment of Patients with ST-elevation 
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Myocardial Infarction (DANAMI-3), which is currently recruiting, aiming for 
recruitment of 1000 participants, and is using magnetic resonance imaging to 
quantify infarct size out to three months after acute myocardial infarction.  
 
1.8.3 Remote Ischaemic Preconditioning (RIPC) 
The benefits of ischaemic conditioning may also be seen when a distant organ 
undergoes pre-emptive ischaemia. This is referred to as remote ischaemic 
preconditioning, and was initially described by Przyklenk who performed IPC 
in dogs and used the circumflex artery as the IPC stimulus, and the LAD as 
the vessel undergoing the prolonged ischaemic insult, with a significant 
reduction in infarct size (104). Perhaps this could be considered as “regional” 
IPC. However, this phenomenon has been shown in liver cells (105), and in 
the brain after limb ischaemia (106) and a reduction in renal and cardiac 
damage was observed after cross clamping the iliac arteries prior to repair of 
aortic aneurysm (107) – this has been termed remote IPC. Remote IPC has 
been shown to reduce troponin release in patients undergoing elective 
coronary intervention (108), surgery on children with congenital cardiac 
defects (109) and coronary artery bypass surgery (110). Recent data in 
humans has supported that inducing transient limb ischaemia by inflating a 
cuff at high pressure to a distant limb prior to complex cardiac surgery 
attenuates release of markers of myocardial damage (CK) and reduces length 
of intensive care stay (111).  
Disappointingly, not all trials of RIPC have demonstrated beneficial effects 
(112,113) and none has translated to an improvement of survival. In fact, the 
most recent study investigating RIPC in patients undergoing high risk CABG 
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has shown an increase in the degree of myocardial injury in the group treated 
with RIPC (205).   
It is clearly difficult to clearly define the benefit of the trials of interventions 
such as RIPC. There are a number of reasons for this. Firstly, the patient 
groups investigated are widely heterogeneous. Additionally, there has been 
no clinical trial carried out to determine the optimum conditioning protocol. It is 
possible that the protocol used widely at present – as described by Kharbanda 
et al (207), may be subtherapeutic in some groups of patients (206). Timing of 
RIPC stimulus in relation to the ischaemic episode is also critical, and varies 
amongst the clinical trials (208, 209). Anaesthetic agents used in the trials are 
also relevant. As discussed in chapter 3, the halothane anaesthetic agents 
have been shown to be cardioprotective in experimental infarction (180-182), 
and this may prevent any demonstration of protection. This is borne out by the 
fact that the studies showing a positive effect of RIPC have not used 
halothane anaesthesia (209, 210), and the studies showing no benefit have 
used the halothanes (208, 211). However, the issue remains far from clear. 
Currently, the Effect of Remote Ischaemic Preconditioning on Clinical 
Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery 
(ERICCA) study is being undertaken. This study is using a number of 
indicators to assess the potential benefit of IPC, such as mortality, major 
adverse cardiac events, troponin release and duration of stay in intensive 
care, amongst a variety of other indicators. The target for recruitment is over 
1700 patients, which may permit demonstration of any potential treatment 
effect more clearly than previous small scale trials.  
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1.8.4 Remote Ischaemic Perconditioning 
The term perconditioning refers to the application of an ischaemic stimulus to 
a remote organ after the onset of ischaemia and before reperfusion occurs. 
The most obvious potential clinical application of this is in the setting of acute 
myocardial infarction whereby inflation of a blood pressure cuff can be used 
as the stimulus, and can be applied before the patient even arrives at hospital. 
In the context of acute myocardial infarction (STEMI) trials have shown benefit 
in terms of myocardial salvage in patients with a large area of myocardium at 
risk, as measured a reduction in myocardial salvage index by SPECT (114), 
but the same study does not show any reduction in mortality or overall 
occurrence of heart failure. Thus far, there is no data which confirms an actual 
benefit in terms of overall improvement in left ventricular ejection fraction / 
heart failure / mortality after remote “perconditioning”. This is a major limitation 
of these trials and this is driven by the fact that the trials are not adequately 
powered to detect such differences. Subgroup analysis may suggest that in 
high- risk groups (ie those with an area at risk of over 35% of myocardium), 
left ventricular function may be improved by remote preconditioning (115). 
However, as with all subgroup analyses, these results must be interpreted 
with caution, and further studies are required to fully evaluate this method of 
cardioprotection in the setting of STEMI. On reviewing clinical trials underway 
in this regard, there are 8 studies described on www.clinicaltrials.gov ongoing 
at present to assess the effect of “conditioning” in acute myocardial infarction, 
reflecting the need for more data on this subject. 
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Author 
 
Intervention 
 
No of 
pts 
 
Ischaemia 
duration 
 
Timing  
 
 
Outcome 
 
Piot et al 
 
Cyclosporin 
A116 
 
58 
 
< 5 h 
mean 
 
Within 
1 min 
of 
PPCI 
 
Reduced CK 
release 
Ma et al Post-
conditioning103 
94 < 12 h Within 
1 min 
of 
PPCI 
Reduced CK, 
improved TIMI-
frame count & 
change in WMSI 
Staat et al 
 
Post-
conditioning102 
30  < 6 h Within 
1 min 
of 
PPCI 
Reduced CK, 
Improved blush 
grade 
 
Thibault et 
al 
Post-
conditioning117 
38 < 6 h Within 
1 min 
of 
PPCI 
Increased LV 
ejection fraction at 
6 months 
Laskey et 
al 
Post-
conditioning118 
24 < 6 h After 
flow 
wire 
Improved CFR & 
ST- segment 
resolution 
Yang et al Post-
conditioning119 
41 < 6 h 30 
secs 
Reduced infarct 
size by SPECT, 
reduced CK 
Thuny et al Post- 
conditioning222 
50 < 12 h Within 
1 Min 
of 
PPCI 
Reduced infarct 
size at 48-72h post 
MI 
 
Table 1.1 Successful conditioning treatments in humans with acute 
myocardial infarction treated by primary percutaneous coronary intervention 
Key to abbreviations in Table 1.1: 
h = hours, PCI = percutaneous coronary intervention, PPCI = primary 
percutaneous coronary intervention, CK = creatinine kinase, TIMI frame count 
= thrombolysis in myocardial infarction frame count, a measure of myocardial 
perfusion, WMSI = wall motion score index- a measure of left ventricular 
systolic function, LV = left ventricle, CFR = coronary flow reserve- a measure 
of microvascular function, ST- segment resolution = improvement in the 
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electrocardiogram indicative of reperfusion, SPECT = single photon emission 
computed tomography,  
 
1.9 Non-mechanical cardioprotection 
1.9.1 Pharmacological Cardioprotection 
The role of pharmacological agents as conditioning-mimetics has been 
investigated extensively both in the laboratory and clinical setting of acute 
myocardial infarction. The earliest studies examined the role of inhibition of 
xanthine oxidase by allopurinol (120,121) in animal models. Further 
translational studies have been conducted with a myriad of agents including 
adenosine (122), erythropoietin (123,124) and lately, the most notable 
success is with the cyclophilin D inhibitor cyclosporin A (116), which is 
discussed in more detail in section 1.9.2. 
A reduction in infarct size has been demonstrated by a variety of 
pharmacological agents known to inhibit the MPTP when administered at 
reperfusion. This includes the volatile anaesthetics (178-180) and cyclosporin 
A (116), amongst many others. The signalling cascades involved are the 
same as those recruited during ischaemic pre and post-conditioning (226).  
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1.9.2 Cyclosporin A 
Cyclosporin A is an undecapeptide produced by the fungus tolypocladium 
inflatum. It was introduced clinically in the 1980s to combat rejection of 
transplanted organs in humans, and has been shown repeatedly to be 
partially cardioprotective in ischaemia-reperfusion injury (23-27). Its primary 
site of binding is cyclophilin D, which is known to be an essential component 
of the MPTP (125). It also inhibits the calcium- dependent phosphatase 
calcineurin, which is responsible for its suppressive effect on the immune 
system. The non-cardiac effects of this drug- nephrotoxicity, 
immunosuppression, potential cancer risk and very narrow therapeutic index 
(126) make it unattractive for ongoing therapeutic use. The benefit of 
cyclosporin A in reduction of myocardial damage in animal models has been 
well established54, but in humans its use has been controversial (127,116)  
Use of non-immunosuppressive (ie without calcineurin inhibition) cyclophilin D 
inhbitors (sanglifehrin A (54), Debio 025 (14), NIM811 (128)) in in vivo models 
of ischaemia-reperfusion injury also demonstrate significant cardioprotection, 
suggesting that cardioprotection is not mediated by calcineurin inhibition, but 
by inhibition of cyclophilin D.  
However, calcineurin itself exerts an effect on the mitochondrion. Under 
normal resting conditions, mitochondria are maintained in a constant 
equilibrium of fusion and fission. Predominance of one or other states leads to 
either cell survival or cell death respectively. Calcineurin has been shown to 
be necessary for the process of mitochondrial fission, which is a well 
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described process in the death of this organelle (129). Dynamin- related 
protein-1 (Drp-1) is dephosphorylated in response to calcineurin activation, 
which occurs when the mitochondrion is exposed to a sustained rise in 
cytosolic calcium level and mitochondrial depolarisation, resulting in fission. 
Inhibition of the fission process by administration of the pharmacological Drp-1 
inhibitor mitochondrial division inhibitor-1 (MDIVI-1) has been shown to delay 
MPTP opening and protect the heart from ischaemia-reperfusion injury (130). 
It is possible therefore, that cyclosporin A protects by both inhibition of 
calcineurin and cyclophilin D. 
Cyclosporin A does remain a promising therapy in myocardial infarction, but at 
the price of its renal and immunosuppressive effect. One large scale clinical 
trial is currently recruiting patients with acute myocardial infarction to 
determine its effects when administered at reperfusion- the pilot data from this 
group suggests that there are potentially significant benefits to be seen in 
terms of infarct size reduction (116).  The calcineurin- related effects could 
potentially be reduced by subcellular drug targeting. This is discussed in more 
detail in the next section. 
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1.10 Targeting drug to site of effect 
In this thesis, we aim to explore the role of the MPTP in cardioprotection from 
ischaemia-reperfusion injury, and in this section, we discuss the 
mitochondrial-specific targeting of a drug known to inhibit cyclophilin D, the 
main component of the MPTP.  
The use of therapeutic drugs is often substantially limited by the inability to 
access the site of action in adequate concentration to achieve its desired 
clinical effect. In the specific case of ischaemia-reperfusion injury, the most 
attractive target is not determined at organ or cellular level, but at a 
subcellular level. The organelle at the centre of the pathological changes is 
the mitochondrion, the function of which is a critical determinant of cell death 
after ischaemia-reperfusion (57). As such, this represents the major 
therapeutic target.  
An ideal drug for cardioprotection therefore, would be one which maintains the 
cardioprotective effect of cyclophilin D blockade, whilst avoiding the 
deleterious effects of inhibition of extra mitochondrial cyclophilins and 
calcineurin. 
1.10.1 Nanocarriers 
By modifying a drug to facilitate its access to its site of action, one of the 
primary concerns is the maintenance of its therapeutic effect, which may be 
compromised by conjugating the drug to other molecules. The aim is that 
modifications would increase the treatment effect, but in trying to do so, it is 
possible that the drug could be rendered metabolically inactive. A group of 
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compounds known as nanocarriers have been developed which enable 
facilitated uptake of pharmacological agents to their target sites. 
To gain selective access to mitochondria molecules require to be 
“mitochondriotropic”- ie they must be able to accumulate within the inner 
mitochondrial membrane despite its high membrane potential. Nanocarriers 
have been shown previously to enable specific uptake of drugs to 
mitochondria (131).  A variety of molecules may be used for this purpose. 
Amongst these is the triphenylphosphonium cation. 
1.10.2 The Triphenyl- phosphonium Cation 
The triphenyl- phosphonium (TPP) cation was initially utilised as a method of 
exploring the electrical properties of phospholipid bilayers in organic 
chemistry. Latter years have shown these molecules to be invaluable in the 
investigation of mitochondrial function, with particular respect to measurement 
of the mitochondrial membrane potential (214).  
In addition these molecules enable confirmation of mitochondrial localisation 
of labelled substances and facilitate accumulation of bioactive molecules and 
drugs within mitochondria. There are a number of examples of this in the 
literature (215).  
 In an attempt to selectively utilise the desirable aspects of cyclosporin A 
(inhibition of cyclophilin D), whilst potentially suppressing its deleterious 
effects (calcineurin and extra-mitochondrial cyclophilin inhibition), a unique 
mitochondrial- targeted cyclosporin A molecule (mtCsA) was developed by 
Professor David Selwood at University College, London.  
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This method of producing “mitochondriotropic” drugs is well described in the 
literature (132-134). The lipophilic triphenyl-phosphonium molecule is 
commonly used for this purpose as it can be conjugated to therapeutic agents 
and is effectively electrophoresed into the negatively charged mitochondria by 
utilising the membrane potential.  
 
 
 
Figure 1.4 The triphenyl-phosphonium cation. 
 
The mtCsA molecule was tested and found to inhibit cyclophilin D inside 
mitochondria preferentially over extra-mitochondrial cyclophilin A in an in vitro 
model. It was also seen to reduce cell death in hippocampal neurons which 
were exposed to oxygen and glucose deprivation- ie energy failure (135). The 
molecule could potentially have significant benefits in vivo in reducing 
myocardial damage in ischaemia-reperfusion, with the benefit of having a 
more selective site of action, avoiding calcineurin mediated effects and also 
allowing dose reduction due to increased selectivity.  
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The potential benefits in the clinical setting of acute myocardial infarction are 
obvious- delivery of a more efficacious drug to a specific site of action 
reducing the required dose and potential side effects, whilst maximising the 
degree of cardioprotection. 
In chapter 5 of this thesis we set out in the first in vivo study of mitochondrial 
targeted cyclosporin A to test the hypothesis that its administration in an in 
vivo murine model of ischaemia-reperfusion will be cardioprotective. 
 
1.11 Non-cyclophilin- D dependent methods of 
cardioprotection 
The aim of this thesis is to investigate the role of the MPTP (cyclophilin D) in 
the myocardial damage which occurs after ischaemia-reperfusion. The focus 
of the introduction so far has been on interventions which aim to prevent or 
delay pore opening in order to reduce cardiac injury. 
Cyclophilin D ablation is known to provide partial protection from ischaemia-
reperfusion injury. However, a degree of cardiac damage still occurs, both in 
CypD knock- out mice exposed to I-R injury (13,54), and in wild type mice 
treated with MPTP inhibitors (12,14,136). This raises the possibility that there 
may be another pathway which results in cell death in this setting. 
Recent evidence appears to support this theory. Roubille et al has published 
data which counters previous belief that it is not possible to protect the heart 
by ischaemic postconditioning after the first few minutes of reperfusion after 
an ischaemic insult, resulting in myocardial damage which is irreversible in the 
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absence of therapeutic intervention during this time (137). This paper shows 
that it is possible to achieve cardioprotection using a protocol of 
postconditioning applied at a period of up to 30 minutes after reperfusion in an 
in vivo mouse model. This suggests that the time window during which 
cardioprotection can be achieved is substantially longer than was previously 
believed (138).  The implication of this is that the cardioprotection in this 
setting may not all be MPTP mediated.  
As discussed previously, the MPTP remains closed during ischaemia, but 
opens in the first few minutes of reperfusion (44), and most of the data 
published previously has suggested that after this time, the myocardium is not 
salvageable (137,139). However, experimental protocols investigating 
postconditioning exhibit widespread variations not only in timing of the IPOC 
stimulus, but also duration of index ischaemia and species. This, coupled with 
the strong bias of learned journals to report only positive data make it difficult 
to clearly establish protocols which have been previously tested (140).   
This data provides an interesting challenge to what has been regarded to be a 
widely held belief that all necrotic cell death is pore mediated. 
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1.11.2 Matrix Metalloproteinases 
 
Matrix metalloproteinases (MMPs) are neutral zinc endopeptidases which are 
present throughout the body. They were first discovered approximately 40 
years ago (141) and play an essential role in regulation of the continual 
process of degradation and synthesis of collagen within the extracellular 
matrix as part of an ongoing homeostatic process. MMPs possess the ability 
to degrade all components of the extracellular matrix. To date, 28 MMPs have 
been confirmed. They are grouped according to their proteolytic functions- eg 
gelatinases (MMP 2 and 9), collagenases (MMP 1, 8, 13), matrilysins (MMP 3, 
10, 11), metalloelastases (MMP 12), stromelysins (MMP 7, 26) and 
membrane type MMPs (MMP 1-8).   
The structure of MMPs is varied, although they possess similar 
characteristics. They are released as inactive zymogens and have a pro-
peptide attached which protects the zinc activation site. The pro-peptide 
(which is highly conserved amongst the MMPs) is cleaved off by a variety of 
stimuli to reveal the active binding site and enable binding of the zinc ion. It 
has been shown that MMPs are involved in a number of pathological 
conditions- which involve inflammatory processes- rheumatoid arthritis (142), 
heart failure, cancer (143,144) and left ventricular remodelling in the aftermath 
of myocardial infarction (145-147).  
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MMP 2 and 9, the gelatinases, are capable of degrading gelatins and type IV 
collagen in basement membranes. They are both highly expressed within 
human myocardium (148). 
 MMPs are activated early in the time course of myocardial infarction- this has 
been confirmed in MMP 1 (absent in rodents (149)), 2 and 9 in both the area 
at risk and the remote area (150).  Additionally, in an animal model of acute 
myocardial infarction, upregulation of matrix metalloproteinase activity has 
been shown to occur as early as 10 minutes after the onset of coronary 
occlusion (147). Within one minute of reperfusion in an ex vivo system, it has 
been shown that MMP -2 is upregulated, and is strongly correlated to 
mechanical dysfunction. In the same group of experiments, treatment with a 
known inhibitor of MMP activity (doxycycline) was shown to reverse this effect, 
demonstrating recovery of contractility (151). This raises important questions 
about the role of MMPs in ischaemia- reperfusion injury.  
Preconditioning has also been shown to modify MMP activity (152,153), and 
in an hyperlipidaemic rat model, where the benefits of IPC are attenuated, 
administration of an inhibitor of MMPs has been shown to result in significant 
cardioprotection (154), which suggests that blocking MMP activity results in 
protection by a means which is disparate to that of IPC, and that these 
mechanisms may potentially be additive. 
1.11.2.1 Regulation of Matrix Metalloproteinases 
Transcription 
MMPs are controlled on three main levels- transcription, activation of latent 
proenzyme and inhibition by TIMPs (tissue inhibitor of metalloproteinases). 
Cara Hendry 
 
53 
A wide variety of stimuli have been shown to increase the synthesis of MMPs. 
This includes IL-1, IL-6, TNF- ɑ, epidermal growth factor, platelet derived 
growth factor and CD40 (155).  
1.11.2.2 Tissue Inhibitor of Metalloproteinases 
Four TIMPs have been discovered in humans (TIMP1-4). They are the 
predominant method of intracellular regulation of matrix metalloproteinase 
activity. Each form of TIMP is encoded by a single gene. Under normal 
circumstances, TIMPs and MMPs act to maintain a constant state of 
equilibrium within the extra cellular matrix of the myocardium (156).  
Dysregulation of this homeostatic mechanism –by upregulation of MMP 
activity, or downregulation of TIMP activity results in adverse remodelling 
within the extracellular matrix of the myocardium and causes disruption of the 
collagenous architecture. 
Blockade of the matrix metalloproteinase system has been shown to reduce 
hepatic damage after ischaemia-reperfusion (157).  Inhibition of MMPs has 
also been to reduce infarct size to a similar degree as that observed after 
preconditioning (158). 
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1.11.3 Pharmacological Inhibition of Matrix Metallproteinases 
MMPs may be inhibited in a variety of ways. It is known that α-2 
macroglobulin is a non – selective irreversible inhibitor, and has been 
described as the major plasma inhibitor of MMPs (159). Heparin is also known 
to be an exogenous inhibitor (160).  
An extensive list of synthetic, so-called small molecule inhibitors of MMPs 
have been developed, but clinical trials of the MMP inhibitors have proven to 
be disappointing – many drugs have been shown to have troublesome side 
effects seen in phase II clinical trials, and as a result beneficial results have 
yet to be seen, with the exception of use of doxycycline which is used to treat 
periodontal disease. Interestingly, the development of side effects in these 
drugs appears to be cumulative and dose related: in the case of marimastat 
(tested in pancreatic cancer) the severe side effects developed after 56 days 
with a dose of 75mg twice daily and 199 days with a dose of 25mg once daily 
(161). This has also been demonstrated in animal models. 
The most common side effect encountered appears to be the 
“musculoskeletal syndrome”, a condition whereby treated patients develop 
joint pains, stiffness and reduction in range of movement.  
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Ilomastat  
 
 
 
Figure 1.5 Ilomastat  
Ilomastat (R)- N4 – Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-
ethyl]-2-isobutyl-succinamide (otherwise referred to as Galardin, GM6001) 
belongs to the group of MMP inhibitors referred to as hydroxamates. It has a 
broad spectrum of MMP inhibition, inhibiting MMP 1, 2, 9 and 12. 
The hydroxamates act as chelators and also block ADAMs (A disintegrin and 
metalloprotease) proteins and TACE (tumour necrosis factor ɑ convertase). 
They may potentially chelate other metalloproteins as they have a binding 
affinity to iron, nickel and copper.  
The cardioprotective effect of ilomastat has been shown to persist even in a 
population of hyperlipidaemic rats (158) Hyperlipidaemia attenuates the effect 
of IPC, by a mechanism which is not fully understood, but has been proposed 
as being due to a reduction in cardiac nitric oxide availability (162,163) and 
increased apoptosis (164) . The finding that MMP inhibition can protect the 
heart in a model which is resistant to IPC raises the possibility that MMP 
inhibitor- induced cardioprotection is mediated by a pathway which is distinct 
to that of IPC, and thus not mediated by the MPTP.
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In chapter six of this thesis, we set out to investigate whether the 
cardioprotection conferred by administration of ilomastat at the time of 
reperfusion is independent of cyclophilin D, a component of the MPTP. 
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Chapter 2 
Summary, Aims Objectives and Hypotheses 
2.1 Summary 
The organelle at the centre of the processes resulting in cell death after 
myocardial ischaemia- reperfusion injury is the mitochondrion, and thus it is of 
great interest when therapeutic treatments to reduce the degree of cell death 
are being considered. 
The central process which is involved in lethal reperfusion injury is the 
opening of the mitochondrial permeability transition pore (MPTP).  
A variety of methods have been used to attempt to reduce this potentially 
reversible injurious process. These include mechanical methods such as 
ischaemic preconditioning (IPC) and ischaemic postconditioning (IPOC) and 
utilisation of cardioprotective drugs (eg cyclosporin A and its analogues).  
These interventions are targeted at inhibition of MPTP opening. 
Mice deficient in cyclophilin D, which has been shown to be central to MPTP 
function, have been shown to be resistant to the effects of ischaemia- 
reperfusion (I-R), but nonetheless display a degree of myocardial damage 
after I-R injury, albeit much reduced in comparison to their wild type brethren. 
They appear to be resistant to further protection by standard IPC protocols.  
Preliminary, unpublished work, by Di Lisa et al, has questioned this, raising 
the possibility that these mice have a raised threshold for IPC, and that this 
may be overcome by increasing the IPC stimulus. In addition, the same group 
have shown (unpublished) work (Appendix) which shows that treatment with 
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agents known as “congenia inhibitors”  (small molecule MPTP inhibitors) in 
combination with cyclosporin A results in improved calcium retention capacity 
(ie reduced MPTP opening) in comparison to cyclosporin A alone. In an ex 
vivo model, these agents also showed a better reduction in infarct size than 
cyclosporin A. Nakagawa also showed that in cyclophilin D deficient mice, the 
MPTP could be induced by administration of high doses of calcium, raising the 
possibility that the MPTP is subject to a threshold phenomenon (165).  
 
The work detailed above questions whether there may a threshold effect of 
pore inhibition. In chapter four, we set out to investigate whether it is possible 
to protect the cyclophilin D deficient mouse by increasing the IPC stimulus. 
 
Cyclosporin A is known to achieve its cardioprotective effect by binding to 
cyclophilin D in mitochondria, thus inhibiting the MPTP. However, its potential 
clinical utility is limited by its calcineurin- mediated (extra-mitochondrial) side 
effects of immunosuppression and deleterious effect on renal function. 
Targeting of cyclosporin A to mitochondria by use of nanocarrier particles 
could potentially achieve cardioprotection, whilst avoiding these detrimental 
effects, and could also potentially require smaller doses to achieve MPTP 
inhibition. In chapter 5, we investigate whether administration of a novel 
mitochondrial-targeted form of cyclosporin A is cardioprotective in its first in 
vivo use. 
 
Data published by Ferdinandy’s group also highlights the possibility that the 
MPTP may not be the only pathway to cell death after ischaemia-reperfusion. 
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The ability to protect hyperlipidaemic hearts from this injury (which previously 
has not been possible by IPC - the strongest cardioprotective stimulus) by 
administration of the matrix metalloproteinase (MMP) inhibitor ilomastat 
suggests that its protective effect may not be mediated by inhibition of the 
MPTP. In chapter 6, we administer ilomastat in an in vivo model of ischaemia- 
reperfusion injury to mice deficient in cyclophilin D and their wild type 
counterparts to investigate whether it is possible to achieve cardioprotection 
by a mechanism independent of the MPTP. 
2.2.1Hypotheses 
2.2.1 Ischaemic preconditioning can protect the heart in the absence of 
cyclophilin D 
2.2.1.1 Objectives 
To determine whether mice deficient in cyclophilin D are amenable to 
cardioprotection by ischaemic pre- conditioning 
2.2.1.2 Rationale 
Cyclophilin D has been shown to be an essential component of the MPTP, 
which plays a central role in cell death in the aftermath of acute myocardial 
infarction. Genetic studies have confirmed that mice deficient in cyclophilin D 
are resistant to pore opening in response to calcium (166) and oxidative 
stress (13), and also exhibit smaller infarct sizes when exposed to ischaemia-
reperfusion in the brain (167) and heart (54). 
The reduction in myocardial damage seen in models of ischaemic 
preconditioning, pharmacological preconditioning as well as ischaemic 
Cara Hendry 
 
60 
postconditioning have been shown to be mediated by inhibition of the MPTP 
(73,74,168). 
Previous studies have shown that using standard IPC / IPOC protocols and 
established pharmacological preconditioning-mimetics it is not possible to 
reduce infarct size after ischaemia-reperfusion in the cyclophilin D deficient 
mouse (12,54). 
However, mice deficient in cyclophilin D still display a degree of myocardial 
damage after myocardial ischaemia and reperfusion, suggesting that there 
may be another mechanism of myocyte damage, which is distinct to that 
involving cyclophilin D.  
2.2.1 Hypothesis: Administration of a mitochondrial specific analogue of 
cyclosporin A will offer superior protection against myocardial damage 
in comparison to cyclosporin A 
2.2.2 Objectives 
To determine if it is possible to achieve superior cardioprotection by the 
administration of a novel mitochondria-selective form of cyclosporin A (mtCsA) 
in mice exposed to ischaemia-reperfusion. 
2.2.3 Rationale 
 
Opening of the MPTP has been shown to be a key step in the death of cells 
after ischaemia-reperfusion. Cyclophilin D is an essential component of the 
MPTP, and ablation of cyclophilin D is known to exert a protective effect on 
the heart exposed to ischaemia- reperfusion. The primary binding site of 
cyclosporin A is cyclophilin D, but it also binds to extra-mitochondrial forms of 
Cara Hendry 
 
61 
cyclophilin (eg cyclophilin A) and also to calcineurin. This extra-mitochondrial 
binding is responsible for the negative effects of cyclosporin ie renal toxicity 
and immunosuppression.  
It would therefore be desirable to target more specifically mitochondrial 
cyclophilin D in order to selectively inhibit the MPTP, whilst minimising effects 
on extra-mitochondrial cyclophilins. 
Data presented previously by Maloutrie et al (135) has demonstrated that in a 
model of hippocampal neurons subjected to glucose and oxygen deprivation 
ie an “energy failure” model administration of a novel mitochondrial- selective 
form of cyclosporin A demonstrated enhanced cytoprotection in comparison to 
cyclosporin A.  
 
2.3.1 Hypothesis: Inhibition of matrix metalloproteinases may protect the 
heart from ischaemia-reperfusion in the absence of cyclophilin D 
2.3.2 Objectives 
To confirm cardioprotection after administration of an MMP inhibitor at the 
time of reperfusion in an in vivo model of ischaemia-reperfusion injury. 
To determine whether it is possible to protect the myocardium in mice devoid 
of cyclophilin D by treatment with an MMP inhibitor administered at the time of 
reperfusion. 
 
2.3.3 Rationale 
Cyclophilin D is an essential component of the MPTP as discussed previously. 
However, in mice devoid of cyclophilin D, exposure to ischaemia-reperfusion 
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still results in a degree of myocardial damage, although this is reduced in 
extent in comparison to mice retaining Cyp D.  
The possibility therefore exists that there is another pathway distinct from 
cyclophilin D which results in part of the cellular damage which occurs after 
reperfused myocardial infarction.  
Matrix metalloproteinases (MMPs) have long been the subject of study in the 
arena of acute myocardial infarction as their role in collagen turnover is an 
essential part of the remodelling process which occurs in STEMI, and a 
variety of other models of cardiac disease.  
Study of MMPs by Etoh et al has revealed that MMP levels rise in the acute 
phase of myocardial infarction - and are detectable at 10 minutes of ischaemia 
(169), and also that administration of MMP inhibitors results in a degree of 
cardioprotection which is similar to that observed after IPC (154). Additionally, 
hyperlipidaemic rats (resistant to benefits of IPC) when exposed to ischaemia-
reperfusion exhibited cardioprotection when treated with an MMP inhibitor 
(158).  
This led us to question whether administration of an MMP inhibitor at the time 
of reperfusion would be cardioprotective in a manner which was independent 
of cyclophilin D. 
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Chapter 3 - Methods 
3.1 General 
In order to establish the role of the mitochondrial permeability transition pore 
in cardioprotection, a mouse model of in vivo ischaemia-reperfusion injury was 
selected. The unique genetic malleability of the mouse - in particular the 
availability of mice deficient in cyclophilin D (an essential component of the 
MPTP), enabled evaluation of whether cardioprotection after a variety of 
interventions was possible in these knockout mice in comparison to the wild 
type.  
All experiments were carried out in accordance with the United Kingdom 
Home Office Guidance on the Operation of Animals for Scientific Procedures 
Act (A(SP)A)1986. 
Mice were allowed water and feed ad libitum, and were exposed to standard 
12 hour dark / light cycle. 
All experiments were carried out on male mice to ensure maximum uniformity 
of infarct size, as data has recently been published which suggests that the 
infarct size and remodelling post myocardial infarction may vary between the 
sexes (170). 
Male mice were bred in - house from a colony with a B6Sv129F1 background, 
which were deficient in Cyclophilin D (Cyp D -/-), provided to us by Baines et 
al (13). These had been back-crossed twice, which maintains a genetic 
background which has approximately 87.5% of B6Sv129F1 DNA. We used 
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cyclophilin D (Cyp D +/+) mice, created by breeding male with female 
homozygous +/+ mice as our wild type controls. Similarly, the Cyp D -/- mice 
were bred from homozygotes. Genotyping was carried out on a random basis 
to ensure correct allocation. 
3.2 Chemicals and Drugs Used 
Cyclosporin A (Tolypocladium inflatum) was supplied by Calbiochem (Merck, 
Nottingham, UK). Mitochondrial targeted cyclosporin A was synthesised and 
produced by Professor David Selwood (Head of Biological and Medicinal 
Chemistry Wolfson Institute for Biomedical Research, University College 
London). Ilomastat and TTC were supplied by Sigma Aldrich, UK. Anaesthetic 
drugs – ketamine, xylazine and atropine were obtained from Fort Dodge 
Animal Health Ltd (UK), Millpledge Veterinary (UK), and Lameln 
Pharmaceuticals (UK) respectively. PCR reagents were obtained from Qiagen 
(UK). 
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3.3 In vivo mouse ischaemia-reperfusion recovery model 
In order to attempt to replicate the human situation of myocardial infarction 
and subsequent reperfusion, we sought to set up an in vivo model recovery 
model of ischaemia-reperfusion in the mouse. The intention was that this 
would enable non- invasive in vivo assessment of myocardial function and 
geometry, and permit serial measurements of changes over time using 
magnetic resonance imaging with gadolinium enhancement. This method of 
assessing ventricular geometry and infarct size has been well validated in 
mouse models of myocardial infarction (171-175). 
Mice were anaesthetised using ketamine (75mg/kg) and medetomidine 
(1mg/kg) administered in a small volume (approx 0.4ml) using a short 27G 
needle (176).  
The mouse was placed into a warmed cage, observed continuously and 
removed after three minutes, by which time it was adequately anaesthetised. 
The hind limb reflex was then checked to confirm adequate depth of 
anaesthesia. 
The neck and chest areas were then shaved using an electrical clipper, and 
cleaned with chlorhexidine solution. 
The mouse was then positioned for intubation in the supine position on an 
electrical heating pad, with the upper limbs abducted and lower limbs 
extended and taped down.  
The neck was extended by threading a suture behind the incisors and 
maintaining this under gentle tension, securing it to the heating pad with tape. 
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A rectal thermometer was lubricated with Vaseline and inserted to provide 
contemporaneous temperature measurements. Temperature was maintained 
at 37ºC (+/-0.5). 
A small midline incision was made on the skin of the neck (1-1.5cm). Using 
blunt dissection, the salivary glands were separated and the paratracheal 
muscles exposed and split along the midline fascia and deflected laterally. 
They were retained in this position by a blunt hook stay on either side. This 
enabled direct visualisation of the trachea. 
 
Figure 3.1 Visualisation of the trachea 
A stainless steel cannula (Hugo Sachs, Germany) was then passed through 
the oral cavity and by direct visualisation through the cervical incision, into the 
trachea. The cannula was attached at its other end, to a plastic Y connector 
which was in turn connected to a ventilator (Minivent Mouse Ventilator, Hugo 
Sachs Electronik, Germany) set at 0.2 ml volume, 120 stroke/min with 
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supplemental oxygen supplied by an oxygen cylinder set at 1.5l/min. This was 
maintained under positive end expiratory pressure (PEEP) by immersing the 
exhaust from the ventilator in 3cm H2O. 
After establishing ventilation, a dose of buprenorphine was administered 
(0.05mg/kg IM), to ensure the animal was pain free post operatively. 
The position of the mouse limbs was then altered to facilitate the surgery. The 
right hindlimb was first placed in an extended position and secured with tape. 
The left hindlimb was then placed over the right hindlimb and was also 
secured by tape. This position facilitates exposure of the heart and left 
anterior descending artery for cardiac surgery. 
An oblique skin incision was made (approximately 1cm) reaching from the left 
sternal border to 1-2mm inferior to the left axilla (4th intercostal space). 
Blunt dissection was then used to separate the skin from connective tissue 
layers and the pectoral muscles were exposed. Pectoralis major and minor 
were then separated and held in place by hook stays taped down to the 
heating pad to maintain gentle tension. 
The ribs were then opened at the 4th intercostal space. Any bleeding was 
terminated by use of low temperature cautery. The chest was held open by a 
mini-Goldstein retractor. 
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Figure 3.2 Use of retractors to expose the heart 
The pericardium was teased apart and the heart exposed. 
A suture (8/0 prolene) was hooked under the left anterior descending artery 
approximately 1mm distal to the tip of the left atrium. 
The system described by Marber et al (177) was then used to temporarily 
occlude the left anterior descending coronary artery, using a short piece of 
PE-50 tubing threaded over the 8/0 prolene suture and using this to act as a 
snare. A short piece of PE-50 tubing (0.28 x 0.61mm) was also placed over 
the surface of the LAD to prevent it from being lacerated by the tightening of 
the suture. The distal tip of a pipette was then passed over the suture needle 
(tip first), and a short segment of PE 50 tubing was placed inside the pipette 
tip and this created a brake system (see figure overleaf). 
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Figure 3.3 The snare arrangement 
The heart was allowed to stabilise for fifteen minutes prior to occlusion of the 
LAD. 
The suture was then tightened over the LAD for a period of thirty minutes. 
The tubing was removed from the LAD to initiate reperfusion, and the prolene 
suture retained in position and loosely tied off. 
Two interrupted 5/0 mersilk sutures were applied to close the ribs. The first (in 
the lateral position) was tightened first and before tightening the second 
suture, gentle pressure was applied to the thoracic cavity in order to expel any 
air and prevent formation of a large pneumothorax. The second suture was 
subsequently tightened. 
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The pectoral muscles were then gently replaced in their original position and 
the skin was closed with individual interrupted sutures (5/0 mersilk). 
The wound was then cleaned with alcohol. 
The anaesthetic was reversed with Atipamezole (5mg/kg IP). 
The mouse was kept on the heated pad with supplemental oxygen until it 
recovered sufficiently, and was then returned to a warmed cage with access 
to water and diet, and was carefully supervised until it was fully ambulant.  
A further IM dose of buprenorphine was administered at 6 and 18 hours post 
operatively. 
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3.4 Problems Encountered with the Ischaemia-reperfusion 
Recovery Model 
In attempting to set up this model (not previously established in our centre) 
difficulties were encountered.  
Using C57 mice to set up the model, firstly permanent infarction (where 
instead of using the snare arrangement, the LAD was occluded by tying off 
the prolene suture) was carried out to confirm that the animal could be safely 
recovered. The length of procedure from administration of anaesthesia 
approximated 30 minutes for this, and recovery was good. All sham 
operations (suture passed, but not tied off) survived. 
However, with an initial stabilisation period of 35 minutes to standardise for 
three cycles of ischaemic preconditioning, and a sham operation, with a total 
anaesthetic time of 105 minutes, the operative survival was poor (10/24 mice). 
Despite a number of manoeuvres to improve this, including administration of 
warmed intraperitoneal saline at the start of the procedure to prevent 
dehydration resulting from prolonged open- chest procedure, the figure could 
not be improved upon. 
Advice was sought from centres with an established recovery protocol and 
these centres used isoflurane as the anaesthetic of choice, both for induction 
and maintenance of anaesthesia, and also reported problems with survival 
when utilising injectable anaesthetic agents. We had initially elected to avoid 
the use of isoflurane in view of its cardioprotective properties (178-180). There 
Cara Hendry 
 
72 
is a body of evidence supporting the fact that its mechanism of protection 
converges on the pathways involved in ischaemic preconditioning eg, 
inhibition of apoptosis, phosphorylation of protein kinase C, attenuation of 
ROS generation and delayed opening of the MPTP (178,181-183). This could 
potentially reduce the ability to detect a reduction in infarct size from a novel, 
potentially cardioprotective agent. However, in view of the problems with 
survival using injectable anaesthetic agents, isoflurane was used for 
subsequent procedures with 100% survival in the sham group with 
anaesthetic time of 105 minutes, and 71% in the ischaemia-reperfusion group. 
Due to the extensive time taken to progress to this stage, and the limited time 
remaining to perform experiments, it was felt appropriate to switch to a non-
recovery model in view of the need to perform further refinement of the 
technique in order to carry out a longitudinal study. 
 
 
3.5 Non recovery model of ischaemia and reperfusion 
Mice were anaesthetised with a combination of ketamine, xylazine and 
atropine, which was administered intraperitoneally. The total volume 
administered was 0.01ml/gram body weight. Final concentration of ketamine, 
xylazine and atropine was 10mg/ml, 2mg/ml and 0.06mg/ml respectively (54).  
Once sufficient anaesthesia was achieved (confirmed by absence of the 
hindlimb reflex), animals were placed in the supine position, with the forelimbs 
abducted and taped down, and the hindlimbs extended and taped to a 
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warmed heating pad. The whiskers were also taped down to extend the neck 
(see fig below) 
.  
Figure 3.4 Preparation and positioning for tracheotomy 
Animals were then tracheotomised and ventilated using a rodent mini-
ventilator (Type 845, Harvard Apparatus, Kent) at a stroke volume of  220 
microlitres and ventilatory rate of 120/minute. Supplemental oxygen at a rate 
of 1.5l/min was administered. 
Body temperature was monitored continuously using a rectal thermometer 
(Hanna, K couple HI 8757) and was maintained at 37ºC +/- 0.5º C.  
Electrocardiographic monitoring was carried out using a standard three lead 
recording of limb lead I.  
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Figure 3.5 .In vivo set up (non-recovery model) 
 
The external jugular vein and carotid artery were dissected out and 
cannulated with a length of PE-50 tubing for drug administration, (both of 
which had been shaped with a flame to create a finely tapered tip) and 
monitoring of intra-arterial blood pressure respectively.  
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Figure 3.6 In vivo set up during experimental protocol 
Both electrocardiogram and intra-arterial blood pressure were recorded using 
Chart 5 for Windows® software (AD Instruments, UK). 
Using the method described by Fisher et al (177), animals were placed in 
position for thoracotomy. The skin was reflected and pectoralis major exposed 
and reflected back, as was pectoralis minor. A thoracotomy incision was made 
at the level of the 4th intercostal space, exposing both atria and ventricle 
beneath a thin layer of pericardium. The pericardium was gently teased apart 
using blunt forceps to expose the ventricle and the left anterior descending 
coronary artery (LAD) was seen as a bright orange vascular structure running 
from the atrium in a caudal direction to the apex of the ventricle.  
An 8-0 prolene® synthetic monofilament (Ethicon, UK) suture was then 
passed around the LAD, at around 2mm from the inferior border of the atrium. 
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This was passed through a snare, fashioned from a short piece of PE 50 
tubing tied to the end, and a D200 pipette tip with a piece of PE 50 tubing to 
act as a brake (see recovery model).  
The animal was then maintained under anaesthesia for a maximum period of 
35 minutes (varied according to experimental protocol- see figure 3.6). This 
period is known as stabilisation. The snare was then tightened for 30 minutes 
to achieve ischaemia, which was confirmed by a drop in mean arterial 
pressure (figure 3.9) and the presence of ST segment elevation / depression 
on the electrocardiogram (see figure 3.8). 
Figure 3.7 ECG during stabilisation 
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Figure 3.8 ECG during ischaemia 
Figure 3.9 Expected blood pressure change during 5 minutes preconditioning 
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 At the end of 30 minutes ischaemia, the snare was released and the LAD 
was reperfused for a period of two hours, after which time the heart was 
harvested and placed on ice.  
A two hour reperfusion period was selected as it has previously been 
demonstrated in the murine ischaemia-reperfusion model to optimally 
demonstrate the infarct size with 2,3,5 triphenyltetrazolium chloride (TTC) 
staining (77). 
3.6 Characterisation of the model  
 
Commercially available C57BL6 black mice (Harlan, UK) were used to confirm 
that myocardial protection was achieved after a single five minute period of 
IPC prior to 30 minutes of sustained ischaemia, with two hours of reperfusion. 
 
 
Figure 3.10 Cardioprotection achieved after one cycle of IPC in C57BL6 
(p<0.005). N=5 in each group. Error bars denote SEM (standard error of the 
mean) 
 
IS/AAR% = infarct size expressed as a % of the area at risk 
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3.7 Exclusion Criteria 
Mice with any evidence of barbarism were excluded. Also, mice were 
excluded if there was absence of a drop in mean arterial blood pressure or if 
there was no change in electrocardiogram after the snare was applied. 
Additionally, if the mean arterial pressure during the stabilisation period was 
<90mmHg, or if significant operative bleeding or the animal did not survive the 
2 hour reperfusion period it was excluded. 
3.8 Assessment of infarct size 
Use of Evans Blue and 2, 3, 5 TTC 
The heart was harvested from a midline incision and dissected out beneath 
the level of the aortic arch. To ensure an adequate length of aorta is obtained, 
it is recommended that the thymus is removed with the heart- within which the 
aortic arch resides. The connective tissue was dissected away to facilitate 
rapid cannulation of the aortic root (less than 3 minutes) and the heart was 
then perfused with 1ml of physiological (0.9%) saline in order to remove any 
residual blood. This was followed by injection of 10ml of 1% 2,3,5 
triphenyltetrazolium chloride (TTC). TTC reacts with dehydrogenases to form 
a deep red (formazan) pigment. It is injected over 1-2 minutes in a small 
beaker to ensure staining of the external surface of the heart in order to 
delineate viable myocardium (stains red, infarcted areas remain unstained). 
Use of TTC in measuring infarct size is a standard, well validated method 
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(184). After this, the LAD suture was re-tied and 1ml of 0.5% Evans Blue was 
injected to determine the area at risk (AAR), delineated by absence of Evan’s 
Blue dye. The area not at risk is stained with Evans Blue.  
The heart was then blotted dry and weighed. 
The heart was frozen at -20ºC for a minimum of 2 hours and then sectioned in 
the short axis from apex to the level of the suture, creating 5 slices of 
approximately 1mm thickness. The slices were then rinsed in physiological 
saline and bathed in 10% neutral formalin solution for 90 minutes at room 
temperature.  
The right ventricle was then removed by careful dissection, leaving the left 
ventricle for analysis. 
The slices were then placed sequentially between two transparent Perspex 
blocks and secured for photography. This was then scanned using a standard 
colour scanner using 1200 bit colour definition (Epson®) into a computer for 
analysis (Figure 3.10). 
 
 
Figure 3.11 Typical example of stained heart before analysis
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3.9 Image J 
 
Image J software devised by the National Institute for Health, USA, (a public 
domain Java image processing domain which is freely available for use 
without license) was used to analyse the heart slices to determine the area at 
risk and infarct size.  
Image J facilitates computerised planimetry of the ventricle by splitting the 
colourisation of photographed images into red and green wavelengths. Red is 
used to highlight the areas stained by Evans Blue and green to highlight the 
infarcted area. By altering the threshold, it is possible to accurately planimeter 
the surface area for each region (see figure 3.12). This is digitally measured 
by pixel counts for each slice and the totals for each slice are added to 
achieve the result for the entire left ventricle. 
Figure 3.12 Outline of left ventricle. 
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Figure 3.13 Red image to delineate the Evans Blue staining 
Figure 3.14 Highlighted areas show Evans Blue staining. 
 
Figure 3.15 Green image delineating infarcted areas (pale). 
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Figure 3.16 Automated planimetry highlighting areas of infarction 
The area at risk (AAR) is expressed as a percentage of the left ventricle 
(AAR/LV%), and the infarct size is expressed as a percentage of the area at 
risk (IS/AAR%). 
3.10 Genotyping 
3.10.1 Digestion  
Ear snips were taken from a random sample of mice at intervals to confirm 
correct genetic allocation. Each sample was placed in a 0.5 ml 
microcentrifuge tube and 180 µl of Direct PCR Lysis Reagent ® was added, 
along with 20µl of Qiagen proteinase K (Sigma). This was then mixed using a 
vortex and incubated at 55ºC overnight. The following morning each sample 
was vortexed for 15 seconds to ensure adequate mixing had taken place. This 
was then replaced in the heating block for 30-45 minutes and the temperature 
was then increased to 85ºC in order to denature the proteinase K, thus 
preventing continued lysis. The samples were then centrifuged for 10 seconds 
at 14,000 RPM to precipitate any hairs. 1 microlitre (µl) of lysate was used for 
each 20µl PCR reaction.  
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 3.10.2 Polymerase Chain Reaction 
All PCR reagents were kept on ice throughout. They were centrifuged and 
vortexed briefly before use. The reagents used are listed in the table below. A 
‘stock mix’ of PCR reagents was prepared, which contained sufficient quantity 
for the number of samples present, a positive control and distilled water 
control. 
 
Reagent Volume per sample 
Qiagen 10 x PCR buffer 
CL 
2.0µl 
10MM dNTPs 0.4µl 
Primer 1 Exon 3F 0.2µl 
Primer 2 Neo F 0.2µl 
Primer 3 Exon 4R 0.2µl 
Taq Polymerase 0.2µl 
Distilled Water 15.8µl 
Total 19µl 
Table 3.1 Reagents for PCR 
19µl of PCR ‘stock mix’ was then pipetted into fresh, labelled micro -PCR 
tubes, and to each of these, 1µl of DNA sample was added. The tubes were 
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all tapped gently, then centrifuged briefly, to ensure that the DNA was fully 
immersed in the reagent mixture. These tubes were then placed into the DNA 
engine (Peltier Thermal Cycler) and subjected to a saved protocol as follows: 
 
Reaction time Process 
1. 95ºC Double stranded DNA separation 
2. 95ºC Double stranded DNA separation 
3. 59ºC Annealing of primers 
4. 72 ºC DNA synthesis 
5. 95 ºC Double stranded DNA separation 
6. 57 ºC Annealing of primers 
7. 72 ºC DNA synthesis 
8. Repeat stages 5-7 for 32 cycles DNA Amplification 
9. 72 ºC DNA synthesis 
10. 4 ºC Storage 
Table 3.2 Protocol for DNA amplification 
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3.10.3 Gel Electrophoresis 
2% agarose gel was made up in Tris – Acetate - EDTA (TAE) buffer with 1µl 
of SYTO 60 ® (Invitrogen, UK) 
A standard gel block (with a wide comb) was used, the edges of which were 
tightly secured with autoclave tape.  
2.0 grammes of agarose powder was added to 100ml of 1 x TAE solution in a 
conical flask. This was rotated gently to dissolve the agarose. This solution 
was then microwaved on high power for 90 seconds. After cooling for 
approximately 5 minutes on a bench, 1µl of SYT060 was added, and rotated 
to mix. This was then aliquotted into the gel block and left to set for 
approximately 15 minutes. 
After this time, the tape was removed from the set gel and placed in the 
central block of the Thermo apparatus. The gel combs were then gently 
removed, and the Thermo block was then filled to the fill line with TAE buffer. 
The first well was then filled with a molecular weight reference ladder. 15µl of 
water was then added to the second well as a negative control PCR reaction. 
Each of the remaining wells were then filled with 15µl of the test samples. The 
lid was then replaced and the unit attached to a powerpack and set to run at 
120V for 90 minutes. 
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The gels were analysed and recorded using the Li-Cor Odyssey® infra red 
imaging system. The images were exported as high quality JPEG files at 300 
dpi (dots per square inch). An example demonstrating both cyclophilin D 
knock out and wild type genotypes is shown below.  
 
 
 
 
 
 
Figure 3.17 DNA electrophoresis 
1200bp
800bp 
500bp
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 3.11 Statistics 
Data was analysed using Prism software and one way ANOVA followed by 
Tukey’s multiple comparison of means test.  A P value of <0.05 was 
considered to be statistically significant. Results are expressed as means 
±SEM. 
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Chapter 4- Ischaemic Preconditioning in The Cyclophilin D 
Deficient Mouse 
4.1 Ischaemic Preconditioning Study 
4.1.1 Background 
 
As discussed in chapters one and two, cyclophilin D appears to be an 
essential component of the mitochondrial permeability transition pore, which 
has been shown to be a critical mediator of cell death after ischaemia- 
reperfusion (13).  
Prior data has shown that it has not been possible to reduce infarct size in the 
mouse deficient in cyclophilin D when subjected to standard IPC/ IPOC / 
pharmacological preconditioning- mimetics (54).  
Mice devoid of cyclophilin D when exposed to ischaemia – reperfusion exhibit 
a reduced infarct size in comparison to their wild type brethren. The level of 
infarct size resulting from this injurious insult is comparable to that of wild type 
animals treated with a cardioprotective stimulus (IPC/IPOC/cyclosporin A). 
 
There is data which has been published in abstract form by Carpi et al, 
(Appendix 1.1) which may suggest that it is possible to protect the hearts of 
mice devoid of cyclophilin D by increasing the IPC stimulus to three cycles in 
an ex vivo model of ischaemia-reperfusion, and also further work 
(unpublished) by the same group (Contursi et al)- see appendix 1.2, which 
suggests that treatment with small molecule MPTP inhibitors “congenia 
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inhibitors” may result in a superior degree of cardioprotection in an ex vivo 
model than is achieved by administration of cyclosporin A (Appendix 1.2).  
 
These findings challenge the widely held belief that once in a “protected” state 
either by IPC or genetic ablation of cyclophilin D the heart cannot be further 
protected against ischaemia-reperfusion- induced injury. 
  
This has not been demonstrated previously in the literature, but raises the 
possibility that it may be possible to “condition” the heart to a greater extent 
than that achieved by genetic ablation of cyclophilin D, either by increasing 
the preconditioning stimulus, or by administration of novel pharmacological 
agents. If cyclophilin D knock-out animals can be protected from I-R injury, 
this raises the possibility that application of two protective stimuli in the clinical 
setting of myocardial infarction could provide significant benefit. 
4.1.2 Aims 
 
A series of experiments were conducted In order to test the following 
hypothesis: 
Ischaemic preconditioning can protect the heart in mice deficient in 
cyclophilin D 
In this chapter we have set out to assess if it is possible to demonstrate 
cardioprotection from ischaemia-reperfusion in mice devoid of cyclophilin D in 
response to an increase in the IPC stimulus in an in vivo model. 
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4.1.3 Methods 
 
Both wild type and Cyp D deficient mice were subjected to thirty minutes of 
ischaemia followed by two hours of reperfusion. These were randomised into 
receiving either no IPC, a single cycle of IPC or three cycles of IPC. 
 
Animals were anaesthetised and prepared for surgery as described in the 
non- recovery model in chapter 3. To reduce procedural time and minimise 
bleeding for this study the carotid artery was cannulated, but not the jugular 
vein. Thoracotomy was carried out and the pericardium was teased apart to 
expose the ventricle. An 8-0 prolene® suture was placed 1-2 mm beneath the 
caudal edge of the atrium. This was attached to a snare which was tightened 
over the left anterior descending artery to achieve periods of ischaemia and 
released to reperfuse the artery, as described in chapter 3. 
Mice with any evidence of barbarism were excluded (n=1). Also, mice were 
excluded if there was absence of a drop in mean arterial blood pressure (n=1) 
or if there was no change in electrocardiogram after the snare was applied 
(n=0). 
Additionally, if the mean arterial pressure during the stabilisation period was 
<90mmHg (n=2), or if significant operative bleeding or the animal did not 
survive the 2 hour reperfusion period it was excluded (n=1). 
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Firstly, in order to characterise the surgical model and confirm protection from 
a single cycle of ischaemic preconditioning a simple validation study was 
carried out. 
4.2 Characterisation of the model 
Commercially available C57BL6 mice (Harlan, UK) were used as they were 
more readily available than wild type mice, to develop the surgical model. I 
was able to demonstrate cardioprotection after a single 5 minute cycle of 
mechanical ischaemic preconditioning with n=5 in each group as 
demonstrated in chapter 3, figure 3.10.  
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4.3 Experimental Protocols 
 
Figure 4.1 Experimental Protocols 
Animals were anaesthetised and prepared for surgery as described in chapter 
three. All groups were subjected to thirty minutes of ischaemia and 2 hours of 
reperfusion preceded by one of the three protocols outlined above- a control 
group which had 35 minutes stabilisation prior to the 30 minutes ischaemia, a 
group which received a single 5 minute cycle of IPC within 5 minutes prior to 
the 30 minutes ischaemia, and finally, a group which underwent three 
alternating 5 minute cycles of IPC and LAD perfusion prior to the 30 minute 
ischaemia. 
The above experiments were carried out on both cyclophilin D knock out and 
wild type mice.  
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Both genotype and experiments were randomised to in order to minimise 
intra-operator bias.  
All experiments were conducted by a single operator (CH). 
The physiological data relating to these experiments are detailed in the 
subsequent graphs and tables. For each of the graphs, the data shown 
represents the mean +/- SEM.  
Physiological parameters (mean arterial pressure and heart rate) were 
recorded throughout the experimental protocol. In the graphs which follow, the 
timescale is non-linear, in order to highlight the changes in observations which 
occur during the short preconditioning cycles.  
In each graph, the coloured bar describes the experimental protocol. The blue 
bars represent LAD perfusion whilst the black boxes indicate LAD ischaemia. 
Notably, the trend of the mean arterial pressure was, in the control group, to 
remain stable during the stabilisation period, fall during ischaemia and then 
experience a drop at the time of reperfusion, then progressively decline until 
the end of the two hour protocol. 
It was also noted that the MAP during stabilisation was significantly higher in 
the Cyp D knock-out mice (108 v 93 mmHg, p<0.04). This pattern persisted in 
the single cycle IPC data, but was not apparent in the data relating to the 3 
cycle IPC protocol. This would suggest that this was not a true effect related 
to the genotype as it was not borne out in all experiments.  
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4.3.1 Results 
Effect of standard (control) protocol on mean arterial pressure 
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* =P<0.05 
 Figure 4.2 Effect of standard ischaemic protocol on mean arterial pressure 
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
MAP: Mean arterial pressure, measured in millimetres of mercury (mmHg) 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
 
The above data demonstrates the blood pressure profile of the animals which 
were subjected to the standard ischaemic (control) protocol, with 35 minutes 
Stabilisation (35mins) Reoerfusion (120mins) 
Ischaemia 
(30mins) 
* * * * * * * * 
Cara Hendry 
 
96 
of stabilisation followed by 30 minutes of ischaemia and 2 hours of 
reperfusion.  
This data is presented in tabular format below on the next page. The blood 
pressure values shown are the mean arterial pressure recorded in millimetres 
of mercury. The given figure is the arithmetical mean.  
Cara Hendry 
 
97 
 
Table 4.1 Blood pressure tables for standard ischaemic (control) 
protocol 
Stabilisation Period 
Time 
(mins) 
N 5  10 15 20 25 30 35 
MAP 
(mmHg) 
+/+ 
9 93 
(3.01) 
91 
(2.74) 
93 
(1.7) 
95 
(1.68) 
94 
(2.08) 
91 
(1.0) 
93 
(1.59) 
MAP 
(mmHg)  
-/- 
9 108 
(6.38) 
 
108 
(4.86) 
110 
(4.52) 
109 
(4.80) 
107 
(4.44) 
104 
(3.89) 
104 
(4.38) 
P value  0.04 0.01 0.01 0.01 0.02 0.01 0.03 
Ischaemia 
 
Time 
(mins) 
1 5 15 25 
MAP 
(mmHg)+/+ 
77 
(3.79) 
74 
(4.83) 
79 
(3.27) 
77 
(3.14) 
MAP 
(mmHg)-/- 
83 
(4.49) 
 
84 
(5.01) 
83 
(4.04) 
79 
(2.44) 
P value 0.24 0.11 0.29 0.44 
Reperfusion 
 
Time 
(mins) 
1 5 10 15 30 60 90 120 
MAP 
(mmHg)+/+ 
67 
(4.10) 
69 
(5.03) 
71 
(4.43) 
69 
(3.84) 
66 
(3.53) 
60 
(3.10) 
53 
(2.79) 
43 
(3.46) 
MAP 
(mmHg)-/- 
77 
(1.98) 
75 
(2.12) 
75 
(2.26) 
74 
(3.06) 
70 
(3.27) 
62 
(2.91) 
53 
(4.28) 
43 
(3.80) 
P value 0.04 0.26 0.36 0.28 0.58 0.85 0.76 0.98 
 
All data shown as mean +/- SEM 
 
MAP = mean arterial pressure (millimetres of mercury) 
 
+/+ = wild type 
 
-/- = Cyclophilin D knock-out 
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4.4.1 Effect of single cycle of IPC on mean arterial pressure 
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*=P<0.05 
Figure 4.3 Effect of single cycle of IPC on mean arterial pressure comparing 
the blood pressure response in wild type and Cyp D knock-out mice 
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
MAP: Mean arterial pressure, measured in millimetres of mercury (mmHg) 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
 
* 
Stabilisation 
(25min) 
Reperfusion (120mins) 
 
Ischaemia 
(30min) 
 
IPC 
(5min) 
 
Stab 
(5min) 
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Figure 4.3 details the mean arterial pressures for the animals which were 
subjected to the single cycle of ischaemic preconditioning (referred to earlier 
as group B). 
As with the standard protocol, there was a higher baseline MAP in the CypD 
knockouts.  
The tables overleaf show the data presented above for the animals which 
were subjected to a single cycle of ischaemic preconditioning. 
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Table 4.2 Data tables for single cycle IPC protocol 
Stabilisation 
 
Time 
(mins) 
N 5  10  15  20  25  30 IPC 35  
MAP 
(mmHg)+/+ 
6 99 
(4.74) 
97 
(2.15) 
99 
(3.05) 
99 
(2.82) 
101 
(2.77) 
83 
(4.08) 
98 
(2.84) 
MAP 
(mmHg)-/- 
9 110 
(4.20) 
107 
(4.30) 
103 
(2.37) 
102 
(2.72) 
101 
(3.35) 
78 
(3.42) 
95 
(2.17) 
P value  0.10 0.07 0.33 0.49 0.87 0.33 0.44 
 
Ischaemia 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
MAP 
(mmHg)+/+ 
81 
(5.00) 
78 
(4.30) 
81 
(3.53) 
80 
(3.78) 
MAP 
(mmHg)-/- 
82 
(2.86) 
85 
(2.98) 
81 
(2.72) 
76 
(3.24) 
P value 0.87 0.21 0.88 0.36 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
MAP 
(mmHg)+/+ 
77 
(3.45) 
76 
(2.94) 
78 
(3.35) 
72 
(3.34) 
68 
(2.54) 
60 
(2.48) 
49 
(2.82) 
35 
(1.87) 
MAP 
(mmHg)-/- 
71 
(3.94) 
67 
(2.78) 
68 
(2.55) 
68 
(2.38) 
70 
(2.51) 
65 
(3.18) 
48 
(3.92) 
36 
(4.59) 
P value 0.23 0.06 0.03 0.50 0.60 0.68 0.89 0.83 
 
 
All data expressed as mean +/- SEM 
 
MAP = mean arterial pressure (millimetres of mercury) 
 
+/+ = wild type 
 
-/- = Cyclophilin D knock-out 
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4.5.1 The effect of three cycles of IPC on Mean Arterial 
Pressure
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Figure 4.4 The data above demonstrates the blood pressure response to 
three cycles of ischaemic preconditioning  
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
MAP: Mean arterial pressure, measured in millimetres of mercury (mmHg) 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
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The blood pressure response to three cycles of IPC was very similar in both 
wild type and cyclophilin D deficient mice. 
Figure 4.7 demonstrates the temporal changes which occurred during the 
three cycles of IPC protocol. The initial blood pressure is satisfactory, and this 
drops in response to the first cycle of IPC. The pressure rises again, but does 
not fully recover to equate to the initial pressure. The next cycle of IPC follows 
a similar pattern with a large reduction in pressure confirming ischaemia, and 
again with reperfusion, the pressure improves, with partial recovery. Each 
preconditioning stimulus follows a similar pattern, and the mean arterial 
pressure is seen to undergo a graded decline. The period of index ischaemia 
results in a sustained reduction in MAP, and at reperfusion there is a further 
drop in pressure, due to the metabolic insult known as lethal reperfusion 
injury. There is a mild recovery of MAP after some time, and subsequently it 
gradually declines out to the two hour protocol end. 
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Haemodynamic differences observed 
The graphic images appear to demonstrate that there is a significant 
difference in the initial mean arterial pressure recorded between the CypD 
knockout mice and the wild type. To test this hypothesis, a t test was carried 
out to compare the means of the initial MAP readings between all of the 
cyclophilin D deficient mice and all of the wild type mice undergoing the 
experimental protocol. 
The results indicate that there was a statistically significant difference in MAP 
at the outset, with the mean for knock- out mice being higher than their wild 
type counterparts (109mmHg versus 99mmHg respectively).  
However, during the remainder of the protocol the mean arterial pressure did 
not differ according to genotype, so this is not thought to be an important 
effect.
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The data below demonstrates the values of mean arterial pressure recorded 
during the experimental protocol using three cycles of ischaemic 
preconditioning. 
Table 4.3 Data tables for three cycles of IPC protocol 
Stabilisation 
Time 
(mins) 
N 5  10 IPC 15  20 IPC 25  30 IPC 35  
MAP 
(mmHg)+/+ 
6 105 
(3.23) 
89 
(3.86) 
104 
(3.74) 
89 
(4.89) 
95 
(4.61) 
80 
(6.19) 
92 
(4.86) 
MAP 
(mmHg)-/- 
9 108 
(5.47) 
86 
(6.80) 
103 
(3.98) 
84 
(5.17) 
98 
(2.09) 
78 
(4.83) 
97 
(3.00) 
P value  0.67 0.70 0.76 0.51 0.69 0.84 0.34 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
MAP 
(mmHg)+/+ 
67 
(2.65) 
62 
(1.99) 
63 
(1.82) 
62 
(2.43) 
59 
(1.75) 
54 
(2.65) 
48 
(1.98) 
41 
(2.23) 
MAP 
(mmHg)-/- 
70 
(2.69) 
67 
(2.27) 
69 
(2.28) 
67 
(1.80) 
62 
(1.91) 
55 
(2.06) 
47 
(3.31) 
37 
(4.06) 
P value 0.57 0.10 0.14 0.09 0.25 0.71 0.73 0.54 
 
MAP= mean arterial pressure (millimetres of mercury), expressed as the 
arithmetical mean 
 
+/+ = wild type mice, -/- = cyclophilin D knock-out mice
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
MAP 
(mmHg)+/+ 
79 
(6.28) 
75 
(6.27) 
76 
(6.14) 
72 
(3.89) 
MAP 
(mmHg)-/- 
78 
(3.59) 
80 
(3.46) 
77 
(3.07) 
72 
(2.67) 
P value 0.92 0.44 0.91 0.96 
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4.6.1 Effect of control protocol (no IPC) on heart rate profile 
 
* = P<0.05 
 
Figure 4.5 Heart rate profile in response to the control (no IPC) protocol in wild 
type and cyclophilin D- deficient mice 
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
Heart rate is measured in beats per minute (bpm) 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
 
The data is presented in tabular format overleaf. 
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Table 4.4 Heart Rate response to control protocol (no IPC) in wild type 
and cyclophilin D knock-out mice 
Stabilisation 
 
Time 
(mins) 
N 5 mins 10 
mins 
15 
mins 
20 
mins 
25 
mins 
30 
mins 
35 
mins 
CTRL+/+ 
HR(bpm) 
9 446 
(11.15) 
432 
(8.95) 
414 
(8.91) 
407 
(8.14) 
411 
(10.07) 
403 
(9.43) 
393 
(8.23) 
CTRL-/- 
HR(bpm) 
9 418 
(13.12) 
413 
(13.00) 
397 
(14.13) 
400 
(13.84) 
398 
(14.98) 
387 
(16.72) 
400 
(15.63) 
P value  0.92 0.40 0.38 0.83 0.65 0.68 0.45 
 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
CTRL+/+ 
HR(bpm) 
395 
(6.52) 
403 
(9.27) 
389 
(7.84) 
382 
(7.62) 
388 
(7.89) 
363 
(12.35) 
427 
(17.55) 
424 
(11.51) 
CTRL-/- 
HR(bpm) 
410 
(13.56) 
409 
(12.90) 
400 
(14.04) 
396 
(16.34) 
395 
(18.54) 
418 
(13.92) 
428 
(22.03) 
422 
(28.18) 
P value 0.03 0.07 0.05 0.14 0.47 0.03 0.38 0.68 
 
HR = heart rate (beats per minute), expressed as the arithmetical mean. 
 
+/+ = wild type mice 
 
-/- = cyclophilin D knock-out mice 
 
 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
CTRL+/+HR 
(bpm) 
395 
(10.12) 
407 
(7.31) 
393 
(6.25) 
394 
(5.8) 
CTRL-/-HR 
(bpm) 
412 
(14.93) 
421 
(17.14) 
409 
(17.25) 
408 
(15.63) 
P value 0.34 0.46 0.35 0.07 
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4.7.1 Effect of single cycle of IPC on heart rate profile  
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Figure 4.6 Heart rate profile in response to single cycle of IPC (wild type and 
cyclophilin D deficient mice). 
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
Heart rate measured in beats per minute (bpm), expressed as the arithmetical 
mean. 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
This data is presented in tabular format overleaf.  
 
Cara Hendry 
 
108 
Table 4.5  Effect of single cycle of IPC protocol on heart rate 
Stabilisation/IPC  
 
Time 
(mins) 
N 5 mins 10 
mins 
15 
mins 
20 
mins 
25 
mins 
30 
mins 
35 
mins 
IPC1+/+ 
HR(bpm) 
6 426 
(14.86) 
414 
(15.8) 
402 
(16.63) 
396 
(18.79) 
399 
(16.73) 
418 
(18.52) 
412 
(12.40) 
IPC1-/-
HR(bpm) 
9 418 
(13.37) 
413 
(11.56) 
397 
(13.01) 
400 
(10.36) 
398 
(9.35) 
387 
(10.94) 
400 
(12.87) 
P value  0.71 0.96 0.81 0.85 0.80 0.17 0.50 
 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
IPC1+/+ 
HR(bpm) 
417 
(8.15) 
423 
(13.92) 
423 
(14.22) 
411 
(11.75) 
409 
(7.04) 
438 
(13.6) 
451 
(11.83) 
455 
(22.07) 
IPC1-/- 
HR(bpm) 
390 
(7.56) 
395 
(6.97) 
388 
(8.72) 
385 
(11.66) 
398 
(12.10) 
409 
(14.04) 
432 
(16.88) 
443 
(17.81) 
P value 0.03 0.08 0.05 0.14 0.47 0.17 0.38 0.68 
 
HR = heart rate (beats per minute) 
 
+/+ = wild type mice 
 
-/- = cyclophilin D knock-out mice 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
IPC1+/+ 
HR(bpm) 
418 
(13.42) 
423 
(15.05) 
414 
(13.35) 
411 
(10.10) 
IPC1-/-HR 
(bpm) 
410 
(8.49) 
404 
(7.70) 
400 
(9.18) 
389 
(6.56) 
P value 0.62 0.29 0.35 0.08 
Cara Hendry 
 
109 
4.8.1 The effect of three cycles of IPC on heart rate  
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Figure 4.7 Heart rate response to three consecutive cycles of IPC in wild type 
and knock-out mice. 
The blue bars represent LAD perfusion whilst the black boxes indicate periods 
of LAD ischaemia. 
Heart rate measured in beats per minute (bpm) 
 
+/+ = Wild type mice (blue) 
 
-/- = Cyclophilin D deficient mice (red) 
The data is displayed as the mean, with error bars to represent the standard 
error of the mean. 
 
 
This data is shown in tabular format overleaf. 
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Table 4.6 Effect of three cycles of IPC on heart rate on wild type and 
cyclophilin D knock-out mice 
Stabilisation/IPC  
 
Time 
(mins) 
N 5 mins 10 
mins 
15 
mins 
20 
mins 
25 
mins 
30 
mins 
35 
mins 
IPC3+/+ 
HR (bpm) 
6 414 
(12.63) 
446 
(25.36) 
402 
(6.58) 
389 
(5.35) 
408 
(13.78) 
409 
(13.22) 
408 
(13.46) 
IPC3-/- 
HR (bpm) 
9 436 
(9.86) 
415 
(13.58) 
418 
(11.43) 
412 
(12.71) 
417 
(13.56) 
398 
(17.14) 
411 
(17.75) 
P value  0.20 0.27 0.30 0.20 0.63 0.64 0.91 
 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
IPC3+/+ 
HR (bpm) 
396 
(18.46) 
384 
(17.86) 
381 
(18.67) 
381 
(17.26) 
378 
(19.16) 
391 
(15.82) 
440 
(20.40) 
466 
(28.41) 
IPC3-/- 
HR (bpm) 
415 
(13.27) 
425 
(8.25) 
409 
(11.46) 
401 
(11.89) 
395 
(15.30) 
417 
(26.19) 
413 
(21.66) 
422 
(21.78) 
P value 0.40 0.10 0.20 0.28 0.50 0.47 0.41 0.24 
 
HR = heart rate (beats per minute), expressed as the arithmetical mean. 
 
+/+ = wild type mice 
 
-/- = cyclophilin D knock-out mice 
 
The heart rate profile shows common features in all three groups – initially the 
heart rate is high during stabilisation, and subsequently falls. During 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
IPC3+/+HR 
(bpm) 
392 
(17.52) 
388 
(16.5) 
379 
(16.68) 
390 
(12.56) 
IPC3-/-HR 
(bpm) 
405 
(16.23) 
402 
(12.54) 
402 
(14.01) 
415 
(13.32) 
P value 0.59 0.52 0.30 0.22 
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ischaemia the heart rate rises as expected to maintain cardiac output, and this 
is persistent during the initial reperfusion phase. Later in reperfusion the heart 
rate falls slightly, to rise again at the end of 2 hours reperfusion as the blood 
pressure continues to fall. 
4.9 Haemodynamics 
In two of the experimental protocols it was noted that the initial mean arterial 
pressure was higher in cyclophilin D deficient than in wild type mice. This led 
us to compare the overall initial mean arterial pressure in all groups to assess 
if this was affected by genotype. 
The mean MAP was 109mmHg in the CypD deficient group, and 98.5mmHg 
in the wild type mouse indicating a significant difference, with p of 0.008. 
However, this difference was only present during the first recorded MAP and 
did not persist during the remainder of the experiment and for this reason it is 
unlikely to have had a significant impact on the results obtained. 
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4.10 Uniformity of area at risk (AAR) in IPC study 
0
10
20
30
40
50
60
70
CTRL+/+ IPC1+/+ IPC3+/+ CTRL-/- IPC1-/- IPC3-/-
A
A
R
(%
LV
)
Area at risk in IPC stimulus study 
 
Figure 4.8 Area at risk expressed as a percentage of the left ventricle  
AAR = Area at risk 
 
%LV = percentage of left ventricle  
 
The n number is denoted by the figure appearing in each data column. 
 
As shown in the graph above, the area at risk was uniform between all groups 
within the ischaemic preconditioning study. 
As discussed in the methods chapter, on measuring the infarct size, there are 
two main areas of myocardium identified: the area which stains blue with 
Evans Blue dye, and the area which does not. The area devoid of Evans’ blue 
is the area which is subtended by the left anterior descending artery (LAD). 
This is referred to as the area at risk. It is well established that infarct size is 
influenced by the area at risk(76,185). The area at risk is a potential source of 
variation in infarct size and thus it is important to quantify it, to ensure there is 
no significant difference between the experimental groups. 
 
9 6 6 9 9 9 
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4.11 Effect of increasing the ischaemic preconditioning 
stimulus 
0
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*P<0.05 in comparison to CTRL +/+
Effect of Increasing the IPC Stimulus
 
Figure 4.9 Effect of increasing the IPC stimulus on infarct sizes in wild type 
mice and controls.  
The number of animals is displayed within the columns of data. 
Key to Diagram:  
CTRL refers to mice subjected to control protocol (ie no IPC) 
IPC1 refers to mice subjected to a single IPC stimulus of 5 minutes 
IPC3 refers to mice subjected to three episodes of five minutes IPC 
The WT mice are referred to throughout the chapter as +/+ 
Mice deficient in cyclophilin D are referred to as -/- 
9 6 6 9 9 9 
  
   * *  * 
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 N IS/AAR(%) SEM 
CTRL +/+  9 40.8 2.96 
IPC1 +/+ 6 21.6* 2.95 
IPC3 +/+ 6 23.7* 3.59 
CTRL -/- 9 30.9 3.16 
IPC1-/- 9 28.8 4.43 
IPC3-/- 9 22.5* 2.12 
Table 4.7 Infarct size expressed as a percentage of the area at risk in each 
treatment group 
* = P<0.05 in comparison to wild type control protocol 
 
The data above demonstrates that the application of a single IPC stimulus 
prior to 30 minutes of ischaemia results in a reduction of infarct size from 
40.8% of the area at risk to 21.6% (P<0.05). The use of three IPC cycles did 
not appear to further reduce infarct size.  
There was a trend towards a significantly smaller infarct size in the cyclophilin 
D deficient hearts in comparison to wild type (30.9% v 40.8% respectively). 
There was also a strong trend towards protection in the CypD deficient mice 
receiving 3 cycles of IPC, although this did not reach significance (30.9% v 
22.5%). These findings are discussed overleaf. 
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4.12 Discussion 
The aim of this chapter was:  
1. To test if the myocardium may be protected from ischaemia-
reperfusion in cyclophilin D deficient mice by increasing the 
ischaemic preconditioning stimulus.  
Confirmation of protection in wild type mice 
Firstly, the cardioprotective effect of ischaemic preconditioning by application 
of a single five minute cycle of IPC has been confirmed in wild type mice with 
a significant reduction in infarct size as shown in published data (54,177). 
Cardioprotection after three cycles of ischaemic preconditioning in wild type 
mice was also confirmed in keeping with the above publications (54,177). 
There was no difference observed between the infarct sizes of the wild type 
mice receiving one and three cycles of ischaemic preconditioning, suggesting 
that once preconditioned, these hearts could not be protected further. 
In the group of cyclophilin D knock-out mice, application of a single cycle of 
IPC did not reduce infarct size. This is expected as prior studies have shown 
that it has not been possible to protect Cyp D deficient mice from ischaemia-
reperfusion injury when exposed to standard IPC protocols (54). 
There was a strong trend towards a protective effect in the cyclophilin D 
deficient mice receiving three cycles of IPC. However, this did not reach 
statistical significance. It is possible that using larger experimental groups that 
protection may be seen. The statistical method of comparing multiple 
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measures to a single control may prevent a clear demonstration of such 
benefit. 
In comparing the infarct size in the wild type mice and the cyclophilin D 
deficient mice subjected to ischaemia- reperfusion, there was no statistically 
significant difference between the groups with infarct size expressed as 
percentage of area at risk of 40.8% v 30.9% respectively (p=0.103). Prior data 
would suggest that a significant difference would be expected between these 
groups. 
The control infarct size is in keeping with other series (54) and concurs with 
the infarct size found in C57BL/6 mice detailed as demonstrated in the 
characterisation of the model. It has been described in the literature that 
colony-specific variation of infarct size may occur (186), but as we used only 
one level of back-cross, then bred homozygotes, this would not be expected 
to incur a large variation in infarct size in our study. 
Prior published data (from our centre) has shown a wild type control infarct 
size of 54%, and CypD deficient control infarct size of 27.9% (54). Baines 
described wild type control infarct size of 45% and CypD deficient controls of 
approximately 30% (13). In the experimental groups described in this chapter, 
the wild type control infarct size observed was 40.8%, and in the cyclophilin D 
deficient control mice 30.9%.  
The infarct sizes obtained in the cyclophilin D deficient groups are all similar, 
but the “wild type” controls exhibit varied infarct sizes between studies.  
It is important therefore to consider what exactly represented the “wild type”. 
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4.13 Importance of genetic background 
 
In Baines paper, the wild type animal was a true wild type mouse, which was 
overexpressing cyclophilin D (+/+). In the paper by Lim et al, the “wild type” 
control was a B6129svF1, which was purchased from a commercial breeder 
(Harlan, UK). 
Both wild type and cyclophilin D deficient animals used in the experiments 
described in this thesis were kindly provided by Baines et al. These were 
subjected to backcrossing with a C57BL6 background.  
By this method CypD +/- (heterozygotes) are bred with one another and the 
homozygotes from each litter are discarded. Each subsequent litter results in 
an increase in the homogeneity of the genetic background. (see figure 4.4) 
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Genetic Background 
 
Figure 4.10 Backcrossing of mice with commercially available C57BL6 mice  
At each level of backcrossing genotyping was carried out to identify 
homozygotes from heterozygotes. At each level heterozygotes are interbred 
with the C57BL6 mice. 
The primary aim of backcrossing is to minimise the amount of genome-wide 
heterozygosity. At the third level of backcross, this is limited to 12.5% (ie 100-
87.5%) (187). 
In this thesis this was the level of backcrossing utilised. The heterozygotes 
from the third backcross were then interbred with one another to produce 
homozygous mice. 
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The table below demonstrates the genotypes obtained after breeding 
heterozygotes with one another (table 4.5) 
CypD Allele + - 
+ +/+ +/- 
- +/- -/- 
Table 4.8 Genotypes obtained after interbreeding of heterozygotes. 
 
It has been described in the literature that there is a significant degree of 
diversity in the amount of myocardial damage which results from an ischaemic 
stimulus amongst mice with differing genetic background. Marber’s group 
have described a very significant difference in the volume of infarct measured 
in a Langendorff model of global ischaemia. In this paper, the measured 
infarct sizes vary from 24% in one C57BL6 wild type mouse (MKK3) to 65.8% 
in another C57BL6 based wild type mouse (MAPKAPK2). This is borne out by 
previous data showing that in a model of transient forebrain ischaemia (188) 
and in situ mouse heart undergoing ischaemia-reperfusion (189) that different 
strains exhibit differing vulnerability to ischaemia. 
This data make it unsurprising that the control infarct sizes in this study varied 
between Baines group and previous data from our unit, as the genetic 
background was differing in all three groups. 
In order to clarify this issue further, increasing the n number in each group 
may be one option to determine a true difference between the groups, or 
comparing a smaller number of groups to control is another method which 
may facilitate the demonstration of a difference. It was our aim to minimise the 
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number of animals used in the experiments to comply with Home Office 
regulations. To increase the ischaemic stimulus (ie duration of ischaemia) in 
all groups would be another method of increasing the infarct size and 
potentially demonstrating important differences between the groups.  
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4.14 Was the IPC stimulus sufficient? 
It would have been desirable to assess the effect of a further increase in the 
IPC stimulus, but due to localised damage to the left anterior descending 
artery occurring resulting in increased infarct size and mortality as described 
in the problems section, I did not find this to be feasible using the model 
described. Unfortunately, this is a limitation of this in vivo murine surgical 
model.  There have been other methods of achieving LAD ischaemia, 
described by Eckle et al (212). It is possible that adoption of a different 
surgical model may result in less localised trauma to the LAD, potentially 
enabling more cycles of IPC to be administered. 
Alternatively, to further test this hypothesis, the experiments could potentially 
be carried out in a larger animal model, by using an increased number of IPC 
stimuli. However, in view of the genetic malleability of mice, they are by far the 
most practical option when investigating the effect of ablation of a particular 
gene. 
To further explore the effects of IPC in the cyclophilin D deficient mouse, it 
would be interesting to investigate whether signalling pathways known to be 
involved in IPC (190) are activated after three cycles of IPC, which could 
potentially indicate that there is a threshold effect. If there was found to be 
activation of the RISK pathway, this might prompt further experiments, 
perhaps in a mouse Langendorff model, with a larger n number. This is further 
discussed in the next section. 
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4.15 Should the sample size be increased? 
Using Stata® software (version 10.0), a power calculation was carried out to 
assess whether a larger cohort would be required to achieve statistical 
significance. This demonstrated that to detect a 40% reduction in infarct size 
(ie infarct reduction from 46% to 28% based on previous literature), with a 
confidence level of 0.05, n of 12 in each group would be required. 
To detect a 40% reduction in infarct size in the cyclophilin knock out group 
(from 28% to 17%) the desired n number would be 30 in each group. 
This was considered, but due to both the limited availability of both knock out 
and wild type animals it was not felt to be feasible.  Additionally, we felt that to 
do so would not be in keeping with the basic principles of the Guidance on the 
Use of Animals (Scientific Procedures) Act 1986, which encourages reduction 
of animal use where possible. 
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4.16 Problems Encountered  
In this study, problems were encountered with the surgical model.  
Although administration of one cycle of IPC with recovery of blood pressure 
and resolution of ECG changes was straightforward, when three cycles of IPC 
were undertaken, it was noted that in a number of cases (n=5), by the third 
cycle the arterial pressure and ECG did not resolve.  
Examination of the LAD and left ventricle under the dissecting microscope 
showed that the myocardium remained pale and the LAD did not appear to 
refill. It was assumed that local damage to the LAD had occurred, which would 
result in an increase in the duration of ischaemia. In view of this, the animals 
falling into this category were excluded from the final analysis.  
Hearts from 3 of these animals were examined and the infarct size found after 
2 hours reperfusion was found to be consistent with this theory, with a mean 
infarct size (expressed as % of the area at risk) of 49.79% (higher than the 
control infarct size).  
Additionally, increased mortality was noted (n=6, including the 5 mice which 
had obvious evidence of no-reflow) in the mice randomised to three cycles of 
IPC. These mice were excluded from the overall analysis as they did not 
reach the pre-determined two hour reperfusion end point, at which time the 
infarct size was measured. 
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As discussed in chapter one evidence is emerging to suggest that the MPTP, 
or more precisely, cyclophilin D, is unlikely to be the end effector of a pathway 
to myocardial damage. This was first considered because genetic ablation of 
cyclophilin D does not completely abolish myocardial damage in the setting of 
ischaemia-reperfusion. Further data by Nakagawa et al showed that cells from 
cyclophilin D deficient mice responded normally to a variety of apoptotic 
stimulants (r- Bid, Bad and r- Bax). Additional findings from this paper were 
that it was possible to induce the MPTP by administration of high doses of 
calcium, this would support the idea that inhibition of the MPTP is a threshold 
effect (165). This theory is further supported by research showing that in a 
model of muscular atrophy following denervation, cyclophilin D deficiency did 
not protect against muscular atrophy in response to activation of apoptotic 
pathways after denervation (191) by division of the sciatic nerve. 
Further, unpublished work, described in Appendix 1.1 demonstrates 
cardioprotection by three cycles of IPC in an ex vivo model of ischaemia-
reperfusion. In this series of experiments, not only was the Langendorff ex 
vivo model used- there was also an increase in the duration of ischaemia, 
which may highlight any difference between the groups by increasing the 
control infarct size. This data did show a reduction in infarct size by 
application of three cycles of IPC in the CypD deficient mouse.  
The experiments described in this chapter did not support the hypothesis that 
ischaemic preconditioning can protect the heart in the absence of cyclophilin 
D. 
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4.17 Suggested areas for future study 
Proposed future study would include assessment of signalling pathway 
activation during each protocol to demonstrate upregulation of these survival 
kinases (eg ERK 1 /2, AKT, MAPK) by Western blotting techniques. If there is 
upregulation of this pathway with a higher number of IPC cycles, this may 
suggest that, in fact there is a protective effect, but that our model is too 
insensitive to detect it.  
A cellular model could also be used, for example a model of hypoxia- 
reoxgenation with repeated episodes of hypoxia to mimic the effect of 
ischaemic preconditioning. Both these models have significant limitations in 
their potential clinical applicability – the Langendorff ex vivo isolated perfused 
heart model, although preferred in comparison to cellular models, has the 
disadvantage of requiring differing concentration of drugs, and the full 
biological effect of drug is not assessed as neural and humoral signals are not 
appreciated by this method. 
It would also be useful to carry out a dose – response curve to determine 
whether it would be possible to increase the duration of ischaemia further in 
order to improve the likelihood of detecting a difference between groups. In 
order to minimise animal use, this was not performed due to the low numbers 
of animals available. 
There are alternative methods of achieving experimental LAD occlusion 
described in the literature, for example the “hanging weights” system 
described by Eckle et al (211). This system is reported to potentially reduce 
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the localised damage to the LAD as a result of the application of ischaemia, 
but no formal comparison of these methods has been carried out. For future 
experiments, this model could potentially be taken into consideration for use 
as an alternative. 
Cara Hendry 
 
127 
Chapter 5  
Mitochondrial Targeted Cyclosporin A 
A Pharmacological Intervention Study 
5.1 Background 
Cyclosporin A (CsA) is known to protect the myocardium from ischaemia-
reperfusion injury, and as such is the focus of much research into treatment of 
acute myocardial infarction. Cyclosporin A has a high binding affinity for the 
cyclophilins (peptidyl-prolyl isomerases (PPIases)). This effect is mediated by 
inhibition of cyclophilin D, which is an essential component of the MPTP. The 
MPTP plays a central role in the cell death which occurs after reperfused 
myocardial infarction.However, the cardioprotective effects of CsA are limited 
in vivo by its effect on the extra-mitochondrial cyclophilins (cyclophilin A and 
B). The interaction of CsA and cyclophilin A inhibits the calcium- dependent 
phosphatase, calcineurin.  
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The main therapeutic use of cyclosporin A at present is in 
immunosuppression, an effect which results from its binding to cyclophilin A. 
However, this also results in a variety of non-desirable clinical effects- renal 
and hepatic toxicity, as well as increased susceptibility to cancers. 
Targeting of cyclosporin to mitochondria should in theory abolish these extra-
mitochondrial effects mediated by calcineurin inhibition, whilst maintaining 
inhibition of peptidyl-prolyl isomerase (PPIase) activity, and thus MPTP 
inhibition.  
It is also theoretically possible that therapeutic effect may be possible in a 
lower dose range if the drug has increased affinity for its binding site, which 
could also be clinically beneficial, by avoidance of dose related side effects. 
Previous data has shown that in isolated mitochondria and hippocampal 
neurons deprived of glucose and oxygen administration of a novel 
mitochondrial- targeted mtCsA was cytoprotective (135).  
In this chapter, the aim was to determine in the first in vivo experiment 
whether mtCsA would be cardioprotective in animals subjected to ischaemia-
reperfusion. 
In this chapter, we carried out the first in vivo experiments utilising a novel 
mitochondrial targeted form of cyclosporin A (mtCsA) created by Professor 
David Selwood (Wolfson Institute for Biomedical Research, University College 
London).  
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5.2 Aims 
To prove the hypothesis: Administration of a mitochondrial specific 
analogue of cyclosporin A at reperfusion will offer superior protection to 
the myocardium from ischaemia-reperfusion in wild type mice when 
compared to standard CsA. 
5.3 Methods 
Animals were prepared and anaesthetised as described in chapter 3. In this 
chapter the jugular vein was dissected out and cannulated with P10 tubing in 
order to administer medication to the central circulation safely. In each of the 
experimental groups a fifteen minute stabilisation period was observed before 
the snare was tightened over the left anterior descending artery for a period of 
thirty minutes (index ischaemia). One minute prior to reperfusion, the drug to 
which the animal was randomised was infused slowly through the cannula to 
ensure bioavailability at the time of reperfusion. The snare on the coronary 
artery was then released. Two hours of reperfusion followed.  
Drug was prepared by dissolving in 1% cremophor EL/ethanol solution and 
reconstituted with physiological saline. This was aliquotted into individual 
doses, frozen and was thawed in a water bath at 37ºC and sonicated both 
whilst being reconstituted and again after thawing for five seconds prior to 
administration to aid dissolution (volume 0.1ml). 
 
 
Cara Hendry 
 
130 
5.4 Experimental Protocols 
As the formulated mitochondrial targeted cyclosporin A (mtCsA) had not 
previously been administered in vivo, a selection of doses were used in order 
to create a dose response curve. Given the increased specificity of the drug 
for mitochondria, it was felt that doses lower than the conventional dose of 
cyclosporin used in animal models (10mg/kg) (54) should be used for initial 
investigations. On an arbitrary basis the doses 0.2mg/kg, 1mg/kg and 5mg/kg 
were selected for use. 
Mice with evidence of barbarism were excluded (n=0). Also, mice were 
excluded if there was absence of a drop in mean arterial blood pressure (n=1) 
or if there was no change in electrocardiogram after the snare was applied 
(n=0). 
Additionally, if the mean arterial pressure during the stabilisation period was 
<90mmHg (n=2), or if significant operative bleeding or the animal did not 
survive the 2 hour reperfusion period it was excluded (n=1). 
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Mice were randomised into eight groups as follows: 
1. Wild type vehicle (WT VEH) 
2. Wild type cyclosporin A 10mg/kg (WT CsA) 
3. Wild type mitochondrial targeted cyclosporin A (0.2mg/kg) (WT mt 0.2) 
4. Wild type mitochondrial targeted cyclosporin A (1mg/kg) (WT mt1) 
5. Wild type mitochondrial targeted cyclosporin A (5mg/kg) (WT mt 5) 
6. Cyp D knock out vehicle (KOVEH) 
7. Cyp D knock out cyclosporin A (KOCSA) 
8. Cyp D knock out mitochondrial targeted cyclosporin A (1mg/kg) (KO 
mt1) 
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5.5 Results 
Physiological effect of pharmacological inhibition of 
cyclophilin in wild type mice  
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Figure 5.1 Effect of pharmacological inhibition of cyclophilin D on mean 
arterial pressure 
MAP = mean arterial pressure (millimetres of mercury), expressed as mean 
value +/- standard error of the mean 
Black bar denotes LAD ischaemia, Blue bar denotes LAD perfusion 
WTCsA = Wild type treated with cyclosporin A  
 
WTMITO 0.2 = Wild type treated with 0.2mg/kg mitochondrial targeted CsA  
 
WTMITO 1 = Wild type treated with 1mg/kg mitochondrial targeted CsA 
 
WTMITO 5 = Wild type treated with 5 mg/kg mitochondrial targeted CsA 
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Table 5.1 Effect of pharmacological inhibition of cyclophilin D on MAP  
Stabilisation 
Time (mins) N 5  stab 10  stab 15 stab 
VEH MAP 
(mmHg) 
6 112 
(4.66) 
108 
(3.60) 
106 
(2.76) 
CsA MAP 
(mmHg) 
6 106 
(6.42) 
103 
(7.03) 
102 
(5.52) 
P value 
VEH v CSA 
 0.45 0.51 0.45 
mt0.2MAP 
(mmHg) 
6 116 
(4.00) 
112 
(3.71) 
111 
(2.89) 
P value 
VEH v m0.2 
 0.55 0.43 0.25 
mt1 MAP 
(mmHg)  
6 114 
(7.92) 
104 
(4.74) 
104 
(3.82) 
P value 
VEH v Mt1 
 0.85 0.52 0.70 
mt5 MAP 
(mmHg) 
4 104 
(1.78) 
104 
(2.39) 
105 
(3.66) 
P value  
VEH v mt5 
 0.25 0.46 0.75 
Ischaemia 
 
 
 
 
 
 
 
 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
VEH MAP 
(mmHg) 
91 
(2.23) 
93 
(2.28) 
95 
(3.08) 
87 
(3.35) 
CsA MAP 
(mmHg) 
83 
(6.69) 
87 
(7.73) 
86 
(6.77) 
84 
(6.39) 
P value 
VEH v CSA 
0.22 0.44 0.20 0.66 
mt0.2MAP 
(mmHg) 
93 
(3.91) 
96 
(4.18) 
95 
(4.21) 
96 
(2.80) 
P value 
VEH v m0.2 
0.65 0.47 0.99 0.08 
mt1 MAP 
(mmHg)  
91 
(4.81) 
91 
(2.46) 
94 
(3.49) 
85 
(2.94) 
P value 
VEH v Mt1 
0.90 0.58 0.71 0.69 
mt5 MAP 
(mmHg) 
85 
(1.60) 
92 
(1.03) 
95 
(1.25) 
90 
(2.84) 
P value  
VEH v mt5 
0.10 0.80 0.99 0.53 
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Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
VEH MAP 
(mmHg) 
93 
(2.59) 
88 
(1.09) 
84 
(1.56) 
82 
(2.13) 
81 
(2.58) 
72 
(1.87) 
66 
(2.20) 
58 
(3.36) 
CsA MAP 
(mmHg) 
74 
(8.64) 
75 
(7.08) 
72 
(5.47) 
70 
(5.41) 
65 
(5.06) 
56 
(7.42) 
53 
(7.76) 
46 
(8.77) 
P value 
VEH v CSA 
0.04 0.05 0.04 0.05 0.01 0.03 0.07 0.18 
mt0.2MAP 
(mmHg) 
90 
(3.20) 
83 
(4.26) 
81 
(3.67) 
82 
(2.02) 
78 
(2.40) 
70 
(4.26) 
60 
(3.99) 
47 
(3.51) 
P value 
VEH v 
mt0.2 
0.57 0.21 0.40 0.96 0.49 0.59 0.14 0.04 
mt1 MAP 
(mmHg)  
82 
(5.16) 
85 
(4.62) 
84 
(4.06) 
80 
(3.26) 
77 
(3.37) 
70 
(2.02) 
62 
(2.41) 
51 
(4.37) 
P value 
VEH v Mt1 
0.09 0.56 0.91 0.58 0.32 0.45 0.14 0.23 
mt5 MAP 
(mmHg) 
82 
(2.99) 
89 
(5.63) 
81 
(2.99) 
76 
(2.29) 
74 
(1.65) 
67 
(3.79) 
61 
(2.40) 
53 
(2.21) 
P value  
VEH v mt5 
0.02 0.91 0.26 0.09 0.11 0.22 0.12 0.32 
 
VEH = wild type treated with vehicle only 
CsA = wild type treated with 10mg/kg of cyclosporin A 
mt 0.2 = Wild type treated with 0.2mg/kg mitochondrial targeted CsA 
mt 1 = Wild type treated with 1mg/kg mitochondrial targeted CsA 
mt 5 = Wild type treated with 5 mg/kg mitochondrial targeted CsA 
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5.6 The effect of pharmacological inhibition of cyclophilin D 
on mean arterial pressure in cyclophilin D deficient mice 
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Figure 5.2 Effect of administration of cyclophilin D inhibitors on mean arterial 
pressure (MAP) during the experimental protocol in cyclophilin D knock- out 
mice 
Black bar denotes LAD ischaemia 
 
Blue bar denotes LAD perfusion 
 
MAP expressed as mean +/- standard error of the mean (in millimetres of 
mercury) 
KOVEH = knock-out treated with vehicle  
 
KOCSA = knock-out treated with 10mg/kg cyclosporin A  
 
KOMITO 1 = knock-out treated with 1mg/kg mitochondrial targeted CsA 
 
The data shown above is demonstrated in tabular format overleaf. 
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Table 5.2 Effect of pharmacological inhibition of cyclophilin D on MAP in 
CypD deficient mice 
Stabilisation 
 
Time (mins) N 5  stab 10  stab 15 stab 
VEH MAP 
(mmHg) 
6 121 
(7.32) 
112 
(8.69) 
114 
(8.02) 
CsA MAP 
(mmHg) 
6 113 
(4.74) 
112 
(5.15) 
111 
(6.39) 
P value 
VEH v CSA 
 0.36 0.89 0.78 
Mt1MAP 
(mmHg) 
6 127 
(10.52) 
120 
(10.83) 
113 
(7.40) 
P value 
VEH v Mt1 
 0.62 0.61 0.98 
Ischaemia 
 
 
 
 
 
 
 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
VEH MAP 
(mmHg) 
89 
(8.25) 
93 
(7.70) 
96 
(6.96) 
90 
(5.74) 
CsA MAP 
(mmHg) 
90 
(5.37) 
94 
(3.42) 
92 
(3.34) 
88 
(3.46) 
P value 
VEH v CSA 
0.92 0.97 0.66 0.79 
Mt1MAP 
(mmHg) 
90 
(6.73) 
94 
(6.70) 
95 
(4.97) 
87 
(2.88) 
P value 
VEH v Mt1 
0.88 0.97 0.91 0.69 
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Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
VEH MAP 
(mmHg) 
86 
(6.32) 
84 
(5.98) 
83 
(5.47) 
82 
(5.74) 
76 
(4.87) 
62 
(2.06) 
51 
(3.12) 
36 
(2.08) 
CsA MAP 
(mmHg) 
83 
(3.91) 
82 
(3.79) 
81 
(2.60) 
79 
(2.07) 
76 
(3.55) 
65 
(2.33) 
51 
(2.32) 
38 
(2.69) 
P value 
VEH v CSA 
0.65 0.75 0.69 0.61 0.96 0.36 0.83 0.54 
Mt1MAP 
(mmHg) 
81 
(4.48) 
84 
(4.6) 
85 
(2.93) 
85 
(3.01) 
71 
(3.04) 
66 
(3.33) 
56 
(5.88) 
46 
(7.88) 
P value 
VEH v Mt1 
0.58 0.99 0.72 0.71 0.41 0.31 0.42 0.21 
 
All data expressed as mean value +/- SEM (in parentheses) 
 
 
VEH = knock-out treated with vehicle  
 
CSA = knock-out treated with 10mg/kg cyclosporin A  
 
MITO 1 = knock-out treated with 1mg/kg mitochondrial targeted CsA 
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5.7 Effect of pharmacological inhibition of cyclophilin D on 
heart rate in wild type mice  
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 Figure 5.3 Effect of pharmacological inhibition of cyclophilin D on heart rate 
(measured in beats per minute) during ischaemia-reperfusion. 
Key to Figure 5.3 
Black bar denotes LAD ischaemia, Blue bar denotes LAD perfusion 
 
Data expressed as mean value +/- standard error of the mean 
WTCsA = Wild type treated with cyclosporin A  
 
WTMITO 0.2 = Wild type treated with 0.2mg/kg mitochondrial targeted CsA  
 
WTMITO 1 = Wild type treated with 1mg/kg mitochondrial targeted CsA 
 
WTMITO 5 = Wild type treated with 5 mg/kg mitochondrial targeted CsA 
This data is shown in tabular format overleaf. 
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Table 5.3 Effect of pharmacological inhibition of Cyp D on HR in WT  
Stabilisation 
Time (mins) N 5  stab 10  stab 15 stab 
VEH HR 
(bpm) 
6 388 
(19.31) 
387 
(12.72) 
374 
(15.37) 
CsA HR 
(bpm) 
6 408 
(17.87) 
411 
(13.46) 
393 
(10.08) 
P value 
VEH v CSA 
 0.50 0.24 0.37 
mt0.2HR 
(bpm) 
6 395 
(17.62) 
397 
(14.15) 
404 
(13.44) 
P value 
VEH v mt0.2 
 0.81 0.63 0.17 
mt1 HR 
(bpm)  
6 420 
(22.54) 
408 
(20.32) 
399 
(17.55) 
P value 
VEH v mt1 
 0.31 0.38 0.30 
mt5 HR 
(bpm) 
4 416 
(14.74) 
422 
(26.99) 
410 
(30.54) 
P value  
VEH v mt5 
 0.35 0.21 0.27 
Ischaemia 
 
 
 
 
 
 
 
 
 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
VEH HR 
(bpm) 
352 
(19.55) 
363 
(18.80) 
363 
(13.50) 
376 
(15.84) 
CsA HR 
(bpm) 
389 
(9.34) 
380 
(3.14) 
371 
(7.55) 
386 
(5.87) 
P value 
VEH v CSA 
0.20 0.46 0.65 0.64 
mt0.2HR 
(bpm) 
387 
(9.45) 
393 
(10.83) 
398 
(10.62) 
399 
(12.01) 
P value 
VEH v 0.2 
0.16 0.21 0.07 0.30 
mt1 HR 
(bpm)  
400 
(17.68) 
404 
(15.17) 
389 
(10.43) 
397 
(10.87) 
P value 
VEH v mt1 
0.10 0.13 0.18 0.32 
mt5 HR 
(bpm) 
376 
(15.14) 
377 
(13.60) 
394 
(13.58) 
397 
(14.30) 
P value  
VEH v mt5 
0.44 0.62 0.17 0.41 
Cara Hendry 
 
140 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
VEH HR 
(bpm) 
382 
(18.06) 
387 
(18.55) 
377 
(20.26) 
372 
(17.23) 
387 
(15.04) 
384 
(11.27) 
397 
(17.62) 
436 
(20.48) 
CsA HR 
(bpm) 
392 
(8.43) 
388 
(13.44) 
387 
(9.15) 
386 
(3.81) 
381 
(6.13) 
394 
(7.52) 
426 
(6.34) 
450 
(16.25) 
P value 
VEH v CSA 
0.68 0.96 0.69 0.51 0.76 0.54 0.22 0.62 
mt0.2HR 
(bpm) 
410 
(11.30) 
397 
(15.32) 
405 
(14.97) 
401 
(11.99) 
414 
(13.59) 
421 
(12.15) 
424 
(18.40) 
418 
(10.06) 
P value 
VEH v 
mt0.2 
0.23 0.70 0.30 0.20 0.22 0.048 0.31 0.46 
mt1 HR 
(bpm)  
410 
(13.06) 
409 
(14.97) 
405 
(15.30) 
405 
(13.43) 
389 
(13.44) 
389 
(7.87) 
397 
(15.32) 
417 
(18.36) 
P value 
VEH v mt1 
0.25 0.39 0.30 0.17 0.92 0.79 0.99 0.50 
mt5 HR 
(bpm) 
415 
(16.22) 
407 
(15.68) 
406 
(22.78) 
417 
(18.76) 
407 
(21.43) 
407 
(21.04) 
422 
(31.61) 
453 
(33.12) 
P value  
VEH v mt5 
0.26 0.49 0.38 0.12 0.45 0.34 0.48 0.66 
VEH = wild type treated with vehicle 
CsA = Wild type treated with cyclosporin A  
 
mt0.2 = Wild type treated with 0.2mg/kg mitochondrial targeted CsA  
 
mt1 = Wild type treated with 1mg/kg mitochondrial targeted CsA 
 
mt5 = Wild type treated with 5 mg/kg mitochondrial targeted CsA 
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5.8 The effect of pharmacological inhibition of cyclophilin D in 
Cyp D knock- out mice on heart rate response to ischaemia-
reperfusion 
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Figure 5.4 Effect of pharmacological inhibition of cyclophilin D on heart rate 
(beats per minute) in cyclophilin D deficient mice subjected to ischaemia-
reperfusion  
Black bar denotes LAD ischaemia 
 
Blue bar denotes LAD perfusion 
 
Data expressed as mean value +/- standard error of the mean 
KOVEH= knock-out treated with vehicle  
 
KOCsA = knock-out treated with 10 mg/kg cyclosporin A   
 
KOMITO 1 = knock-out treated with 1mg/kg mitochondrial targeted CsA 
 
The above data is presented in tabular format overleaf. 
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Table 5.4 Effect of pharmacological inhibition of CypD on heart rate in 
cyclophilin D deficient mice 
Stabilisation 
 
Time 
(mins) 
N 5  stab 10  stab 15 stab 
VEH HR 
(bpm) 
6 411 
(14.84) 
407 
(13.51) 
407 
(9.96) 
CsA HR 
(bpm) 
6 411 
(13.88) 
399 
(21.23) 
405 
(14.82) 
P value 
VEH v CSA 
 0.98 0.76 0.91 
Mt1HR 
(bpm) 
6 409 
(22.82) 
404 
(25.13) 
396 
(20.20) 
P value 
VEH v 
mt1 
 0.94 0.91 0.64 
Ischaemia 
 
 
 
 
 
 
 
 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
VEH HR 
(bpm) 
399 
(13.87) 
394 
(13.48) 
399 
(9.48) 
401 
(6.04) 
CsA HR 
(bpm) 
395 
(16.94) 
391 
(17.49) 
391 
(18.45) 
391 
(13.05) 
P value 
VEH v CSA 
0.84 0.91 0.73 0.48 
Mt1HR 
(bpm) 
398 
(22.34) 
376 
(25.24) 
383 
(28.29) 
383 
(16.12) 
P value 
VEH v mt1 
0.98 0.55 0.59 0.21 
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Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
VEH HR 
(bpm) 
424 
(11.86) 
432 
(7.79) 
410 
(7.99) 
407 
(10.15) 
405 
(16.03) 
391 
(11.18) 
401 
(10.35) 
405 
(10.87) 
CsA HR 
(bpm) 
380 
(11.33) 
385 
(11.53) 
393 
(11.67) 
397 
(12.37) 
414 
(12.52) 
422 
(16.28) 
425 
(10.82) 
413 
(11.34) 
P value 
VEH v CSA 
0.02 0.007 0.27 0.55 0.69 0.15 0.14 0.66 
Mt1 HR 
(bpm) 
394 
(13.30) 
400 
(18.64) 
403 
(18.90) 
400 
(26.28) 
385 
(21.22) 
406 
(19.69) 
418 
(20.34) 
423 
(17.20) 
P value 
VEH v mt1 
0.12 0.13 0.75 0.80 0.45 0.51 0.44 0.39 
VEH= knock-out treated with vehicle  
 
CsA = knock-out treated with 10 mg/kg cyclosporin A   
 
Mt1 = knock-out treated with 1mg/kg mitochondrial targeted CsA 
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5.9 Haemodynamic effects of pharmacological inhibition of 
cyclophilin D 
The data above demonstrates that the blood pressure response during this 
experimental protocol is similar within all experimental groups- including both 
cyclophilin D deficient and wild type genotypes.  
The mean arterial pressure tends to drop slightly after the first recording made 
during the stabilisation phase. This is likely due to the stress involved in being 
anaesthetised. It then remains stable during the stabilisation phase and drops 
markedly at the onset of ischaemia (it is one of the findings which confirms 
ischaemia). It then drifts downwards slightly during the period of ischaemia. 
Due to the administration of the fluid bolus containing the experimental drug 
or vehicle, there is a rise in the observed MAP at the beginning of the 
reperfusion phase.  The effect of this is brief, and the MAP gradually declines 
as the protocol continues to its two hour completion, as observed in the 
preconditioning experiments of chapter four.  
The heart rate responses were similar within all groups during the protocol. 
This remained constant throughout the protocol, but towards the end of the 
experiments there was a tendency of the heart rate to rise slightly, as part of 
the haemodynamic response to heart failure. 
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5.10.1 Area at risk in wild type mice  
 
 
 
Figure 5.5 Area at risk in wild type mice subjected to administration of 
cyclophilin D inhibitors at the time of reperfusion 
Area at risk is expressed as a percentage of the left ventricle, and mean value 
displayed +/- standard error of the mean 
N for each group is displayed in each column. 
 
WT VEH= wild type receiving vehicle only  
 
WT CsA = wild type receiving 10mg/kg of cyclosporin A  
WT mt0.2 = wild type receiving 0.2 mg/kg of mitochondrial targeted CsA  
WT mt 1 = wild type receiving 1mg/kg of mitochondrial targeted CsA 
WT mt 5 = wild type receiving 5mg/kg of mitochondrial targeted CsA 
 
The area at risk did not vary significantly amongst the groups. 
 
 
 
6 6 6 6 4 
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5.10.2 Area at risk in cyclophilin D knock out mice 
 
Figure 5.6 Area at risk expressed as a percentage of the left ventricle. 
Data expressed as the mean value +/- standard error of the mean. The n 
number of each group is displayed in the corresponding column. 
KO VEH = knock-out receiving vehicle 
KO CsA = knock out receiving 10 mg/kg cyclosporin A  
KO mt1= knock-out receiving 1 mg/kg of mitochondrial-targeted cyclosporin A  
As shown above, the area at risk was uniform amongst treatment allocations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
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5.11 Effect of cyclophilin D inhibition on infarct sizes after 
ischaemia-reperfusion in wild type mice 
 
Figure 5.7 Infarct sizes obtained after administration of cyclophilin D inhibitors 
to wild type mice at reperfusion 
IS/AAR(%) = infarct size expressed as a percentage of the area at risk 
 
WT VEH= wild type receiving vehicle only  
 
WT CsA = wild type receiving 10mg/kg of cyclosporin A  
WT mt0.2 = wild type receiving 0.2 mg/kg of mitochondrial targeted CsA  
WT mt 1 = wild type receiving 1mg/kg of mitochondrial targeted CsA 
WT mt 5 = wild type receiving 5mg/kg of mitochondrial targeted CsA 
The n number in each group is displayed in the corresponding column. 
 
 
 
6 6 6 6 4 
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Effect of pharmacological inhibition of Cyp D on infarct size 
 
 
 
 IS/AAR (%LV) SEM 
WT vehicle 35.04 1.74 
WT cyclosporin A 23.26 3.33 
WT mt CsA 0.2 34.71 5.93 
WT mtCsA 1 31.89 5.06 
WT mtCsA 5 45.46 4.46 
 
 
Table 5.5 Effect of pharmacological inhibition of cyclophilin D on infarct size in 
wild type mice 
WT vehicle = wild type treated with vehicle  
WT cyclosporin A = wild type treated with cyclosporin A  
WT mtCsA 0.2= wild type receiving 0.2 mg/kg of mitochondrial targeted CsA 
WT mtCsA 1 = wild type receiving 1mg/kg of mitochondrial targeted CsA 
WT mtCsA 5 = wild type receiving 5mg/kg of mitochondrial targeted CsA 
The data above demonstrates that there was a strong, but not significant 
trend towards protection in the group treated with CsA in comparison to 
vehicle (35% v 23%, P>0.05). The groups receiving the lower doses of 
mitochondrial specific CsA exhibited infarct sizes comparable to vehicle 
controls. The group receiving the highest dose of mtCsA showed a higher 
infarct size (not significant) than control, which could suggest that the 
treatment is actually harmful at higher doses. 
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5.12 Effect of pharmacological inhibition of cyclophilin D on 
infarct size in cyclophilin D deficient mice 
 
Figure 5.8 Infarct size obtained after cyclophilin D knock- out mice received 
pharmacological inhibition of cyclophilin at the time of reperfusion 
IS/AAR(%)= Infarct size expressed as a percentage of the left ventricle 
 
N number for each group displayed in the corresponding column 
 
KO VEH = knock-out receiving vehicle 
KO CsA = knock out receiving 10 mg/kg cyclosporin A  
KO mt1= knock-out receiving 1 mg/kg of mitochondrial-targeted cyclosporin A  
 
The data above shows that there was no difference in infarct size measured 
after 30 minutes ischaemia in cyclophilin D deficient mice treated with CsA. 
The administration of mitochondrial-targeted CsA resulted in an apparent 
(non- significant) increase in infarct size observed.  
 
6 6 6 
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Effect of pharmacological inhibition of cyclophilin D on infarct 
size in knock- out mice subjected to ischaemia-reperfusion 
 
 KO vehicle KO cyclosporin A KO mitoCsA 
IS/AAR(%LV) 20.32 19.70 31.32 
SEM 1.33 1.76 10.15 
 
Table 5.6 Effect of pharmacological inhibition of cyclophilin D in knock out 
mice 
 
IS = infarct size 
 
AAR = area at risk 
 
SEM = standard error of the mean 
 
KO vehicle = knock- out receiving vehicle 
 
KO cyclosporin A = knock- out receiving cyclosporin A 
 
KO mito CsA = knock-out receiving mitochondrial targeted cyclosporin A  
  
There was no change in infarct size observed after the administration of 
cyclosporin A in comparison to vehicle control (20% v 20%, P>NS) to Cyp D 
deficient mice. However, when mitochondrial-targeted CsA was given to Cyp 
D deficient mice, there was an increase in infarct size observed. 
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5.11 Discussion 
This group of experiments was designed to test the hypothesis that 
administration of a novel mitochondrial targeted form of cyclosporin A at the 
time of reperfusion in a mouse model of ischaemia-reperfusion injury would 
be cardioprotective. 
From the data represented in fig 5.7, it can be seen that there was no 
evidence of cardioprotection in wild type mice from mitochondrial -targeted 
cyclosporin administered at doses of 0.2mg/kg, 1mg/kg and 5mg/kg just prior 
to the onset of reperfusion. 
As part of this chapter we administered cyclosporin A as a positive control. In 
this series of experiments, when analysed as a group by Tukey’s analysis of 
multiple means (assuming equal variances) this did not demonstrate a 
statistically significant reduction in infarct size.  There was a strong trend to a 
reduction in infarct size, which, when analysed by Student’s T test did appear 
to be significant, with a p value of <0.05. However, when comparing multiple 
groups to a single control, the T test would not be an appropriate statistical 
test to use. This demonstrates the dilution effect of multiple comparisons 
when trying to demonstrate statistical significance. 
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In the cyclophilin D knock- out mice, there was no significant difference 
between the groups. As expected, there was no difference between the Cyp D 
knockouts receiving vehicle and those receiving cyclosporin A. The effect of 
cyclosporin A is mediated by via cyclophilin D, and prior data supports the fact 
that cyclophilin D deficient animals treated with CsA do not show a reduction 
in infarct size after ischaemia-reperfusion (54). 
To minimise the use of animals, in the Cyp D knock -out group only one dose 
of mitochondrial targeted cyclosporin A was tested. The mid-range dose of 
1mg/kg was arbitrarily selected for use in this experiment. Also, use of a 
mitochondrial - targeted molecule would not be expected to confer any 
reduction in infarct size in this group for the same reason. It was interesting to 
note that the infarct size was observed to be higher in the group treated with 
mitochondrial targeted cyclosporin A. This raises the possibility that the 
treatment may be harmful. 
Localisation of mitochondrial specific cyclosporin A to site of action 
To investigate whether the mtCsA reached its intended site of action in 
mitochondria, after terminal anaesthesia with 160mg/kg pentobarbitone, ex 
vivo hearts were perfused with mtCsA labelled with100nM chloromethyl-X-
rosamine (Mito-tracker Red- which labels respiring mitochondria) in a 
Langendorff model using C57BL6 (Harlan, UK) mice by Dr Sean Davidson 
(Hatter Institute).  
Twenty micromoles per litre of blebbistatin (an inhibitor of actin–myosin cross-
bridge cycling) was added to prevent contraction and movement (201).  
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Fluorescence was then excited at 840nm and multi-photon imaging was 
carried out using a Zeiss 510 NLO microscope. Fluorescence was strongly 
localised to cardiomyocyte mitochondria as shown in figure 5.9 below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Fluorescence of cardiomyocyte with loaded with 100 nano-molar 
mtCsA – rosamine 
 
(Reproduced with kind permission of Dr Sean M Davidson (Hatter Institute, 
UCL) 
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Figure 5.10 Fluorescence in heart loaded with TMRM (tetra-methylrhodamine-
methyl ester), which labels respiring mitochondria.  
Reproduced with kind permission of Dr Sean M. Davidson (Hatter Institute, 
UCL). 
 
The images above demonstrate that the fluorescence of the mtCsA is 
approximately 50% of that in the TMRM assay, ie mtCsA has been taken up 
into approximately 50% of respiring mitochondria, thus confirming that it has 
reached its desired site of action.
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In this chapter the pharmacological effect of a novel, potentially 
cardioprotective agent has been studied in both wild type and cyclophilin D 
knock- out mice which have been subjected to myocardial ischaemia and 
reperfusion. 
Cyclosporin A has a high degree of affinity for the Cyclophilins. These are 
proteins which possess peptidyl-prolyl isomerase activity, and leads them to 
be referred as “PPIases” as discussed in chapter 1. This is an essential 
process required for protein folding in vivo. Cyclosporin A inhibits PPIase 
activity in its bound state. Cyclophilin A and B are located in the cytosol and 
endoplasmic reticulum respectively, whilst cyclophilin D is located within 
mitochondria. The function of these proteins varies widely: CypA is involved in 
translocation of apoptosis inducing factor to the nucleus and protection from 
oxidative stress, whilst CypB suppresses the apoptosis involved with oxidative 
stress and altered calcium metabolism. The binding of cyclosporin A to CypA 
results in a drug-protein complex which inhibits calcineurin (a calmodulin and 
calcium- dependent phosphatase) (82). This process is responsible for the 
immunosuppressive effect of cyclosporin A, causing inhibition of interleukin-2, 
tumour necrosis factor -ɑ, interleukin-3, interleukin-4, CD 40L, granulocyte –
macrophage colony stimulating factor and interferon-ɣ (194). In 1990, 
Halestrap and Davidson revealed that CsA inhibited the opening of the MPTP 
by binding to cyclophilin D (52). Cyclophilin D was later confirmed as the 
molecular target of cyclosporin A in 1996 (53).  
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Genetic ablation of cyclophilin D in mice by Baines has since confirmed that 
CypD is the cellular target of cyclosporin A, and that it is essential for the 
function of the MPTP (213). 
Cyclosporin A, as discussed in chapter 1 exerts a cardioprotective effect on 
the myocardium when administered prior to reperfusion. This has been 
reproduced in many models and in a variety of settings (54, 213). However, its 
deleterious effects on the immune system and renal function make it 
undesirable for clinical use. Its effect in clinical trials has also been 
disappointing limited (112, 216). 
The potential benefits of targeting cyclosporin A to mitochondria, and thus 
increasing the selectivity to cyclophilin D are increased potency and abolition 
of these cyclophilin A/ calcineurin inhibitory mediated side effects of 
cyclosporin which involve immunosuppression, renal and hepatic toxicity and 
increased susceptibility to cancers.  
The synthesis of a novel mitochondrial selective form of cyclosporin A 
(mtCsA) thus held much promise. The novel mitochondrial selective 
cyclosporin A (mtCsA) molecule was created by Professor David Selwood 
(University College London), by conjugating cyclosporin A with the triphenyl-
phosphonium cation. The resulting compound (mtCsA) then accumulates into 
the mitochondria by electrophoresis down the proton gradient of the 
mitochondrial membrane.  
In vitro testing of this agent described by Maloutrie et al demonstrated positive 
results, with a reduction in cellular necrosis seen in hippocampal neurons 
subjected to deprivation of glucose and oxygen, which was superior to that of 
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cyclosporin A. Additionally, mtCsA was shown not to inhibit calcineurin, 
thereby potentially avoiding the deleterious effects of cyclosporin A (135). 
The series of experiments detailed in chapter 5 represented the first in vivo 
testing of the mtCsA molecule. There had been no previous work to confirm 
its utility in this setting, nor its bioavailability at the desired site of action. The 
doses selected for use were lower than the experimental dose of cyclosporin 
A on the basis that as the molecule was more specific to mitochondria, the 
dose required would be lower to achieve the desired protective effect. We did 
attempt a dose- response curve to assess the optimal drug dose for use, but 
found that none achieved any benefit in terms of reduction in infarct size. It is 
possible therefore that all doses were either too low to achieve any clinical 
effect, or conversely, were administered at toxic doses. The experiments 
carried out by another researcher in our centre using an ex vivo model (Fig 
5.10) did later confirm that the mtCsA did reach the desired site of action. The 
in vivo effects of mtCsA however, have not demonstrated any benefit in terms 
of reduction in infarct size, despite being tested at a variety of doses.   
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The potential reasons behind this are multiple-  
1. The cyclophilin D binding affinity was not maintained due to structural 
modifications occurring during the manufacturing of the mtCsA 
molecule. 
2. Recent data has shown that the mtCsA molecule required a higher 
dose of mtCsA to block the MPTP than CsA itself (192)  
3. The drug may have a low therapeutic index, resulting in administration 
of toxic doses 
4. The uptake of the drug, administered one minute prior to reperfusion 
via the internal jugular vein in vivo may be insufficient to enter 
mitochondria by the time of pore opening. 
In considering the above scenarios- and taking each in turn, it is possible that 
the altered structure of the mtCsA could potentially reduce the cyclophilin D 
binding affinity as a result of the manufacturing process. The method of 
chemical linkage from the triphenyl-phosphonium cation to CsA uses 
“position-3”, which is required for the insertion of CsA into CypD. As a result, 
there is the potential for sterical prevention of binding to cyclophilin D. 
However, switching to other mitochondrial- targeting agents, such as 
Rosamine, for linkage, had similar effect, with similar reduction in binding 
affinity, suggesting that the TPP molecule was not directly responsible for this 
effect. It has been proposed that the actual linker from mtCsA to CypD may 
have undergone a conformational change resulting in folding back on itself, 
maximising hydrophobic interactions, this reducing access to the binding sites 
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on cyclosporin A. This is borne out by the findings detailed by Dube, whereby 
the adoption of a shorter (ether) linking molecule in combination with the TPP 
molecule has improved the binding affinity of a novel form of mtCsA (192).  
A reduction in binding capacity of mtCsA for cyclophilin D has been confirmed 
in later experiments by Dube et al. (192). 
The suggestion of toxic dose administration, although possible, is unlikely 
given the findings of Dube et al, discussed below.  
The late drug uptake in vivo may remain a possibility, but given that 
cyclosporin A when reconstituted in an identical manner reaches its site of 
action in identical circumstances, is unlikely. Additionally, the mtCsA was 
shown to be present in mitochondria, in an ex vivo model (fig 5.9 and 5.10). 
A recent publication by Dube et al, has discussed the reason for therapeutic 
failure of the initial mtCsA and examines the effect of a new molecule, which 
possesses an 18- fold increase in the cyclophilin D affinity in comparison to 
the molecule we tested, and 12- fold increase in MPTP inhibition. The binding 
affinity of the original mtCsA was studied and was noted to be 1/30 of the 
binding affinity for cyclosporin A (192).  This would suggest that a lack of 
binding affinitity for cyclophilin D is the primary reason for the failure of 
mitochondrial- specific CsA (mtCsA) to protect the heart from ischaemia-
reperfusion injury.  
Proposed future work would involve administration of the second generation 
mitochondrial targeted cyclosporin A to in an in vivo mouse model of 
ischaemia-reperfusion, and demonstrating a dose response curve in order to 
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determine the most effective dose with which to achieve cardioprotection. To 
confirm the molecule reaching the site of action, it would be useful to repeat 
the experiments of Dr Davidson, using mito-tracker red labelled with the 
second generation mtCsA. 
A direct comparison to cyclosporin A could then be carried out to demonstrate 
whether the molecule shows an enhanced degree of cardioprotection in an in 
vivo setting in comparison to cyclosporin A. 
There is great potential utility of a novel mitochondrial- specific cyclosporin. 
However, the effect of mtCsA in our experiments was disappointing for the 
reasons above. However, the recently developed second generation molecule 
does show promise for future use, although much work is required to refine its 
role in cardioprotection. 
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Chapter 6  
 
Non MPTP pathways to cardioprotection 
 
Hypothesis: Inhibition of matrix metalloproteinases may protect the 
heart from ischaemia- reperfusion in cyclophilin D deficiency6.1 
Background 
As discussed in chapter one, matrix metalloproteinases have generated a 
great deal of interest over the last decade. They have been shown to be 
closely involved in the processes which occur in the aftermath of myocardial 
infarction- not only in the setting of the chronic remodelling process post 
myocardial infarction (145,149), but also in the acute stage of ischaemia and 
reperfusion (151).The gelatinases MMP 2 and 9 are highly expressed within 
human myocardium. As their name suggests, they degrade gelatins and also 
type IV collagen, which is present in basement membranes. MMP 2 and 9 
have been shown to be upregulated in the myocardium early in the course of 
myocardial infarction- both in the area at risk and remote myocardium 
(150).MMP-2 has been shown to be upregulated by oxidative stress (217) and 
phosphorylation (218). Both these factors are closely implicated in the 
processes involved in ischaemia – reperfusion.Administration of a non-
selective inhibitor of MMPs has been shown to result in recovery of 
contractility in an ex vivo model of ischaemia-reperfusion (151). 
MMP-2 has also been shown to cleave troponin I in an ex vivo model of 
ischaemia-reperfusion injury, and both troponin I release and the resulting 
mechanical dysfunction has been shown to be reduced by administration of 
doxycycline (a non-selective inhibitor of MMPs) (195).It is possible therefore, 
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that inhibition of matrix metalloproteinase activity could be used to modify the 
maladaptive response of ischaemia-reperfusion injury which occurs on 
opening the occluded coronary artery in the setting of acute myocardial 
infarction.   
To test the hypothesis that cardioprotection could be achieved by a non – 
MPTP dependent mechanism, an MMP inhibitor (ilomastat) was administered 
in an isolated heart preparation using a Langendorff apparatus (see fig 6.1 
overleaf).  These isolated heart experiments (ex vivo) were carried out by 
another researcher in our group (Dr Robert Bell, Hatter Institute, UCL). As this 
group of experiments involved a model of global ischaemia, the measurement 
of infarct size differs; the infarct size is expressed as a percentage of the left 
ventricle (as opposed to percentage of the area at risk in the in vivo 
experiments). 
 
Key to diagram overleaf:   
 
WT Ctrl = Wild type exposed to control protocol 
WT iPoC = Wild type treated with ischaemic post- conditioning 
KO Ctrl = Cyclophilin D knock-out treated by control protocol only 
KO iPoC = Cyclophilin D knock-out treated with ischaemic postconditioning 
KO Ilomastat = Cyclophilin D knock-out treated with ilomastat (0.25 
micromol/L) 
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6.2 Effect of Ilomastat in an Isolated Mouse Heart Model  
(Data presented courtesy of RM Bell) 
 
Figure 6.1 Effect of ischaemic postconditioning and inhibition of matrix 
metalloproteins. Data expressed as mean +/- SEM. Infarct size expressed as 
percentage of left ventricle 
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6.3 Aims 
In order to assess more fully the effect of matrix metalloproteinase inhibition a 
series of experiments were conducted in the in vivo model of ischaemia-
reperfusion.  
6.4 Effect of Matrix Metalloproteinase Inhibition in an in vivo 
model of ischaemia – reperfusion 
6.4.1 Methods 
The series of experiments detailed in figure 6.1 demonstrate that 
administration of an MMP inhibitor resulted in a significant reduction in infarct 
size both in wild type and in cyclophilin D knock- out mice.  
 In order to test the hypothesis that ilomastat would be cardioprotective in vivo 
in the absence of cyclophilin D a set of experiments were conducted as 
follows. 
Both wild type and CypD deficient mice were exposed to a standard period 
(30 minutes) of ischaemia. Those randomised to IPC underwent a single 5 
minute cycle of IPC prior to ischaemia.  
Ilomastat or vehicle control was administered via a central vein less than one 
minute prior to reperfusion. 
Ilomastat was administered at a dose of 6 µmol/kg (154) based on the total 
dose administered by Ferdinandy’s group as 4 separate boluses. The drug 
was dissolved in 1% cremophore/ethanol solution and sonicated for ten 
seconds and was then frozen until the day of use. The aliquots of drug were 
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then placed in a water bath at 37 degrees Celsius until they were defrosted. 
They were then sonicated prior to use to aid dissolution, and injected via a 
P10 cannula placed in the jugular vein one minute prior to reperfusion of the 
left anterior descending artery. 
6.4.2 Randomisation 
Both wild type and cyclophilin D deficient mice were used for this experiment.  
The treatments were randomised into 6 groups as follows (n=6 in each 
group):  
1. Wild type mice receiving vehicle only 
2. Wild type mice receiving ilomastat  
3. Cyclophilin D knock- out mice receiving vehicle only 
4. Cyclophilin D knock- out mice receiving ilomastat 
5. Wild type mice receiving vehicle plus a single 5 minute cycle of IPC 
6. Wild type mice receiving ilomastat plus a single 5 minute cycle of IPC 
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6.5 Results 
Physiological Effect of Inhibition of Matrix Metalloproteinases 
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Figure 6.2 Effect of ilomastat given at reperfusion on mean arterial pressure in 
wild type mice exposed to 30 minutes ischaemia and two hours reperfusion. 
 
Data is expressed as the mean value +/- SEM. 
 
Blue bars denote periods of LAD perfusion, back bars denote LAD ischaemia. 
 
MAP = mean arterial pressure (millimetres of mercury). 
 
+/+ VEH = wild type mice receiving vehicle only 
 
+/+ ILO = wild type mice receiving ilomastat 
 
 
 
This data is shown in tabular format overleaf. 
Cara Hendry 
 
167 
 
Table 6.1 Effect of MMP Inhibition on MAP in wild type mice 
Stabilisation 
 
 
Time (mins) N 5  
stab 
10  
stab 
15 
stab 
+/+VEH 
MAP(mmHg) 
6 112 
(4.66) 
108 
(3.60) 
106 
(2.76) 
+/+ILO 
MAP(mmHg) 
6 115 
(5.28) 
105 
(5.49) 
106 
(3.65) 
P value  0.64 0.66 0.93 
 
Ischaemia 
 
 
 
 
 
 
 
 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
+/+VEH 
MAP(mmHg) 
93 
(2.59) 
88 
(1.09) 
84 
(1.56) 
82 
(2.13) 
81 
(2.58) 
72 
(1.87) 
66 
(2.20) 
58 
(3.36) 
+/+ILO 
MAP(mmHg) 
82 
(5.30) 
80 
(5.64) 
75 
(4.16) 
70 
(3.30) 
66 
(5.14) 
58 
(3.74) 
53 
(7.26) 
44 
(5.91) 
P value 0.09 0.20 0.01 0.05 0.02 0.01 0.09 0.05 
 
MAP = mean arterial pressure (millimetres of mercury). 
 
+/+ VEH = wild type mice receiving vehicle only 
 
+/+ ILO = wild type mice receiving ilomastat 
 
 
 
 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
+/+VEH 
MAP(mmHg) 
91 
(2.23) 
93 
(2.28) 
95 
(3.08) 
87 
(3.35) 
+/+ILO 
MAP(mmHg) 
84 
(4.57) 
86 
(4.97) 
83 
(3.51) 
79 
(4.05) 
P value 0.20 0.27 0.02 0.15 
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Effect of MMP Inhibition on MAP in knock-out mice 
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Figure 6.3 Effect of ilomastat bolus on mean arterial pressure in cyclophilin D 
knock- out mice exposed to 30 minutes of ischaemia and two hours 
reperfusion. 
Data is expressed as the mean value +/- SEM. 
 
Blue bars denote periods of LAD perfusion, back bars denote LAD ischaemia 
 
MAP = mean arterial pressure (millimetres of mercury). 
 
-/- VEH = cyclophilin D knock-out mice receiving vehicle only 
 
-/- ILO = cyclophilin D knock-out mice receiving ilomastat 
 
 
This data is shown in tabular format overleaf. 
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Table 6.2 Effect of MMP inhibition on MAP in Cyclophilin D deficient 
mice 
 Stabilisation 
 
 
Time (mins) N 5  
stab 
10  
stab 
15 
stab 
-/-VEH 
MAP(mmHg) 
6 121 
(7.32) 
113 
(8.69) 
114 
(8.02) 
-/-ILO 
MAP(mmHg) 
7 114 
(4.15) 
107 
(4.94) 
106 
(4.51) 
P value  0.42 0.55 0.38 
 
Ischaemia 
 
 
 
 
 
 
 
 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
-/-VEH 
MAP(mmHg) 
86 
(6.32) 
82 
(5.98) 
84 
(5.47) 
83 
(5.74) 
82 
(4.87) 
62 
(2.06) 
51 
(3.12) 
36 
(2.08) 
-/-ILO 
MAP(mmHg) 
91 
(3.76) 
85 
(1.96) 
83 
(1.72) 
81 
(2.87) 
78 
(3.23) 
65 
(3.72) 
56 
(4.52) 
45 
(5.46) 
P value 0.43 0.88 0.72 0.48 0.18 0.60 0.36 0.17 
 
 
 
 
 
 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
-/-VEH 
MAP(mmHg) 
89 
(8.25) 
93 
(7.70) 
96 
(6.96) 
90 
(5.74) 
-/-ILO 
MAP(mmHg) 
82 
(5.47) 
83 
(3.81) 
83 
(3.54) 
84 
(4.49) 
P value 0.51 0.21 0.10 0.43 
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Effect of IPC and MMP inhibition on Mean Arterial Pressure 
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* = P<0.05 
Figure 6.4 Combined effect of IPC and MMP inhibition on mean arterial 
pressure in wild type mice exposed to a single cycle of IPC, 30 minutes of 
ischaemia followed by 2 hours of reperfusion 
WTVEHIPC= wild type subjected to IPC and administration of vehicle at 
reperfusion 
WTILOIPC = wild type subjected to IPC and administration of the MMP 
inhibitor ilomastat at reperfusion 
MAP = mean arterial pressure measured in millimetres of mercury (mmHg). 
Figures shown as mean +/- SEM. 
This data is shown in tabular format overleaf. 
The bar in the x axis demonstrates periods of ischaemia (black) and 
reperfusion (blue). The timescale is non- linear to highlight the changes 
occurring during ischaemia. 
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Table 6.3 Effect of IPC and MMP inhibition on Mean Arterial Pressure 
Stabilisation 
Time (mins) N 5  
stab 
10  IPC 15 
stab 
+/+VEHIPC 
MAP(mmHg) 
6 118 
(5.95) 
91 
(5.21) 
104 
(6.22) 
+/+ILOIPC 
MAP(mmHg) 
5 100 
(2.08) 
76 
(4.09) 
98 
(3.21) 
P value  0.043 0.06 0.47 
 
Ischaemia 
 
 
 
 
 
 
 
 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
+/+VEHIPC 
MAP(mmHg) 
77 
(5.67) 
74 
(4.67) 
76 
(3.43) 
77 
(3.92) 
76 
(3.92) 
65 
(2.38) 
55 
(4.02) 
43 
(3.41) 
+/+ILOIPC 
MAP(mmHg) 
84 
(5.24) 
77 
(1.53) 
69 
(1.76) 
71 
(3.93) 
65 
(6.44) 
54 
(4.84) 
47 
(1.86) 
36 
(4.00) 
P value 0.43 0.64 0.17 0.35 0.16 0.03 0.16 0.17 
In the tables above +/+ refers to wild type mice, ILOIPC refers to mice treated 
with a single cycle of IPC and ilomastat administered at reperfusion. VEHIPC 
relates to those mice treated with a single cycle of IPC and vehicle 
administered at reperfusion. 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
+/+VEHIPC 
MAP(mmHg) 
91 
(8.46) 
91 
(5.34) 
87 
(5.25) 
82 
(5.38) 
+/+ILOIPC 
MAP(mmHg) 
81 
(3.38) 
78 
(6.03) 
77 
(3.84) 
90 
(7.02) 
P value 0.42 0.13 0.21 0.33 
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Effect of MMP inhibition on heart rate in wild type mice   
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Figure 6.5 Effect of ilomastat on heart rate in wild type mice subjected to 30 
minutes of ischaemia and two hours of reperfusion. 
Data expressed as mean +/- SEM 
 
Blue bars denote periods of LAD perfusion, back bars denote LAD ischaemia 
 
HR (bpm) = heart rate (beats per minute) 
 
+/+ VEH = wild type mice receiving vehicle only 
 
+/+ ILO = wild type mice receiving ilomastat 
 
The bar in the x axis demonstrates periods of ischaemia (black) and 
reperfusion (blue). The timescale is non- linear to highlight the changes 
occurring during ischaemia. 
This data is shown in tabular format overleaf. 
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Table 6.4 Effect of MMP inhibition on heart rate in wild type mice  
Stabilisation 
 
Time (mins) N 5  stab 10  
stab 
15 
stab 
+/+VEH  
HR (bpm) 
6 388 
(19.32) 
387 
(12.72) 
374 
(15.37) 
+/+ILO 
HR (bpm) 
6 442 
(22.19) 
445 
(24.47) 
446 
(22.02) 
P value  0.09 0.06 0.02 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
+/+VEH 
HR (bpm) 
382 
(18.06) 
386 
(18.56) 
377 
(20.26) 
372 
(17.23) 
387 
(15.04) 
385 
(11.27) 
397 
(17.62) 
436 
(20.48) 
+/+ILO 
HR (bpm) 
416 
(20.58) 
435 
(21.8) 
416 
(23.78) 
413 
(22.61) 
411 
(25.45) 
415 
(25.83) 
408 
(16.54) 
417 
(15.15) 
P value 0.24 0.12 0.24 0.17 0.44 0.30 0.67 0.46 
 
HR (bpm) = heart rate (beats per minute) 
 
+/+ VEH = wild type mice receiving vehicle only 
 
+/+ ILO = wild type mice receiving ilomastat 
 
 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
+/+VEH  
HR (bpm) 
352 
(19.54) 
363 
(18.80) 
363 
(13.50) 
376 
(15.84) 
+/+ILO 
HR (bpm) 
410 
(23.67) 
404 
(26.31) 
408 
(23.18) 
405 
(23.67) 
P value 0.09 0.23 0.12 0.33 
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Effect of MMP inhibition and IPC combined on heart rate in 
wild type mice 
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Figure 6.6 Response of heart rate to combination of IPC and MMP inhibition 
in wild type 
Key to diagram 
WTVEHIPC= Wild type animal treated with a single cycle of ischaemic 
preconditioning and vehicle administered one minute prior to reperfusion  
WTILOIPC= Wild type animal treated with a single cycle of ischaemic 
preconditioning prior to ilomastat administered one minute prior to 
reperfusion. 
The bar in the x axis demonstrates periods of ischaemia (black) and 
reperfusion (blue). The timescale is non- linear to highlight the changes 
occurring during ischaemia. 
This data is shown overleaf in the corresponding data tables. 
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Table 6.5 Effect of IPC and MMP inhibition on heart rate in wild type 
 
 
Stabilisation 
 
Time (mins) N 5  stab 10  IPC 15 
stab 
+/+VEHIPC 
HR (bpm) 
6 426 
(18.29) 
399 
(20.20) 
405 
(9.72) 
+/+ILOIPC 
HR (bpm) 
5 407 
(6.43) 
384 
(15.06) 
414 
(21.66) 
P value  0.51 0.63 0.66 
Ischaemia 
 
 
 
 
 
Reperfusion 
 
Time (mins) 1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
+/+VEHIPC 
HR (bpm) 
389 
(17.98) 
382 
(18.78) 
374 
(21.89) 
376 
(22.64) 
385 
(18.08) 
383 
(23.10) 
414 
(27.20) 
410 
(28.12) 
+/+ILOIPC 
HR (bpm) 
421 
(24.59) 
409 
(9.39) 
398 
(17.06) 
409 
(9.45) 
408 
(5.24) 
391 
(14.01) 
393 
(7.62) 
387 
(11.59) 
P value 0.32 0.37 0.50 0.35 0.42 0.84 0.62 0.60 
 
 
+/+ VEHIPC= Wild type animal treated with a single cycle of ischaemic 
preconditioning and vehicle administered one minute prior to reperfusion  
 +/+ ILOIPC= Wild type animal treated with a single cycle of ischaemic 
preconditioning prior to ilomastat administered one minute prior to 
reperfusion. 
 
 
Time (mins) 1  
 I 
5    
I       
15   
I 
25  
I 
+/+VEHIPC  
HR (bpm) 
396 
(13.06) 
393 
(16.07) 
393 
(17.10) 
382 
(17.60) 
+/+ILOIPC 
HR (bpm) 
399 
(14.77) 
399 
(7.69) 
399 
(14.57) 
406 
(16.19) 
P value 0.88 0.79 0.82 0.42 
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Effect of MMP inhibition on heart rate in CypD deficient mice 
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Figure 6.7 Effect of ilomastat on the heart rate profile of cyclophilin D knock- 
out mice subjected to ischaemia-reperfusion 
Data is expressed as the mean value +/- SEM. 
 
On the x axis blue bars denote periods of LAD perfusion, back bars denote 
LAD ischaemia 
 
HR (bpm) = heart rate (beats per minute). 
 
-/- VEH = cyclophilin D knock-out mice receiving vehicle only 
 
-/- ILO = cyclophilin D knock-out mice receiving ilomastat 
 
 
This data is presented in tabular format overleaf. 
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Table 6.6 Effect of MMP inhibition on heart rate in CypD deficient mice 
Stabilisation 
 
Time 
(mins) 
N 5  stab 10  stab 15 stab 
-/-VEH 
HR(bpm) 
6 411 
(14.84) 
407 
(13.51) 
407 
(9.96) 
-/-ILO 
HR(bpm) 
7 402 
(17.79) 
396 
(12.63) 
388 
(15.40) 
P value  0.72 0.56 0.35 
 
Ischaemia 
 
 
 
 
 
 
Reperfusion 
 
Time 
(mins) 
1 
R 
5 
R 
10 
R 
15 
R 
30 
R 
60 
R 
90 
R 
120 
R 
-/-VEH 
HR(bpm) 
424 
(11.86) 
432 
(7.79) 
410 
(7.99) 
407 
(10.15) 
405 
(16.03) 
391 
(11.18) 
401 
(10.35) 
405 
(10.87) 
-/-ILO 
HR(bpm) 
395 
(13.62) 
399 
(12.53) 
403 
(13.73) 
404 
(14.12) 
400 
(15.11) 
408 
(13.66) 
435 
(28.92) 
434 
(16.10) 
P value 0.15 0.06 0.73 0.90 0.82 0.39 0.34 0.20 
 
-/- VEH = cyclophilin D knock-out mice receiving vehicle only 
 
-/- ILO = cyclophilin D knock-out mice receiving ilomastat 
 
Time 
(mins) 
1  
 I 
5    
I       
15   
I 
25  
I 
-/-VEH 
HR(bpm) 
399 
(13.87) 
394 
(13.48) 
399 
(9.48) 
401 
(6.04) 
-/-ILO 
HR(bpm) 
376 
(11.72) 
382 
(13.22) 
383 
(14.33) 
386 
(16.30) 
P value 0.22 0.57 0.41 0.46 
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6.6 Haemodynamic effects 
 
The blood pressure and heart rate responses observed during this group of 
experiments was similar to that found during the preceding chapters, with a 
marked drop in mean arterial pressure confirming onset of ischaemia and 
progressive drop in pressure during the period of reperfusion to the protocol 
end.  
Heart rate remained stable initially, and then rises during the stress of 
ischaemia and subsequently stabilises, finally rising towards the protocol end. 
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6.7 Area at Risk  
 
 
 
Figure 6.8 Uniformity of area at risk amongst all treatment allocations 
 
Area at risk expressed as mean value +/- SEM, as a percentage of the left 
ventricle. N numbers are displayed within the corresponding data columns. 
VEH +/+ = wild type mice receiving vehicle only 
ILO +/+ = wild type mice receiving ilomastat 
VEH -/- = Cyp D knock-out mice receiving vehicle only 
ILO -/- = Cyp D knock-out mice receiving ilomastat 
IPCILO +/+ = wild type mice receiving IPC and ilomastat 
IPCVEH+/+ = wild type mice receiving IPC and vehicle 
The area at risk was uniform for all groups as demonstrated above. 
 
 
 
 
 
6 6 6 7 6 5 
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6.8 Effect of MMP inhibition of on Infarct Size  
 
 
 
Figure 6.9 Effect of matrix metalloproteinase inhibition on infarct size in both 
wild type and cyclophilin D deficient mice 
The infarct size is expressed as a percentage of the area at risk 
 
The n number for each group is displayed in the corresponding data column. 
 
VEH +/+ = wild type mice receiving vehicle only 
ILO +/+ = wild type mice receiving ilomastat 
VEH -/- = Cyp D knock-out mice receiving vehicle only 
ILO -/- = Cyp D knock-out mice receiving ilomastat 
IPCILO +/+ = wild type mice receiving IPC and ilomastat 
IPCVEH+/+ = wild type mice receiving IPC and vehicle 
The * denotes a statistically significant difference (p<0.05) in comparison to 
wild type receiving vehicle control 
 
† denotes a statistically significant difference (p<0.05) in comparison to 
cyclophilin D knock out receiving vehicle control 
6 6 6 7 6 5 
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Effect of MMP inhibition of on Infarct Size 
 
 IS/AAR (%LV) SEM 
+/+ Vehicle  35.04 1.74 
+/+ Ilomastat 21.51* 5.31 
-/- Vehicle  20.66* 1.18 
-/- Ilomastat 10.35*† 1.31 
+/+ Vehicle & IPC 18.65* 3.87 
+/+ IPC and Ilomastat 20.36* 0.43 
 
Table 6.7 Effect of MMP inhibition on infarct size  
 
+/+ refers to wild type mice 
 
-/- refers to cyclophilin D knock-out mice 
 
* = p<0.05 in comparison to +/+ vehicle control 
 
†= p<0.05 in comparison to -/- vehicle control 
 
The data above shows a significant reduction in infarct size after 30 minutes 
ischaemia in wild type animals treated with ilomastat in comparison to those 
receiving vehicle (35% v 22%, P<0.05).  
CypD deficient mice exposed to the same ischaemic protocol exhibited 
smaller infarct sizes than their wild type counterparts. The administration of 
ilomastat to CypD knock-outs resulted in a significant reduction in infarct size 
when compared with those receiving vehicle alone (20.7% v 10.4%, P<0.05). 
Co-administration of ilomastat and IPC did not result in further reduction in 
infarct size in comparison to either IPC or ilomastat alone. 
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6.9 Discussion 
Matrix metalloproteinases (MMPs) play a central role in the maintenance of 
the integrity of the extracellular matrix. There exists a constant equilibrium 
between collagen synthesis and breakdown, mediated by the up- and down- 
regulation of MMP activity and that of tissue inhibitors of metalloproteinases 
(TIMPs). All MMPs contain zinc (Zn2+) at their active binding site.  
There is strong evidence to show that modification of this continuous process 
occurs in the setting of acute myocardial infarction, and a variety of other 
cardiac diseases (170,193,198). In the setting of MI, upregulation of MMP 
activity has been shown to occur within 10 minutes of the onset of ischaemia 
(147). In an ex vivo system, activation has been confirmed within one minute 
of reperfusion, and this is strongly related to mechanical dysfunction. This 
effect has been shown to be reversed by administration of a broad spectrum 
MMP inhibitor (doxycycline) (151). 
The process of ischaemic preconditioning has also been shown to modify the 
activity of MMPs (152,153). Interestingly, in the instance of hyperlipidaemic 
rats, where the benefits of IPC are inhibited, MMP inhibition has demonstrated 
the ability to protect the heart from ischaemia-reperfusion injury (154). This 
could potentially suggest that the cardioprotection achieved by administration 
of MMP inhibitors may occur by a mechanism which is distinct to that afforded 
by IPC. 
Data demonstrating attenuation of cardiac damage in experimental 
myocardial infarction by inhibition of matrix metalloproteinases is plentiful 
(149,154) and as such these agents are of great interest to scientists and 
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clinicians alike in the search for agents which can protect the human heart in 
the setting of reperfused myocardial infarction, a pharmacological role which 
has to date remained unfilled (199). The pharmacological inhibitors of MMPs 
belong to the class hydroxamates, which inhibit MMPs by binding of 
hydroxamic acid to the Zn2+ site of MMP. 
Ilomastat belongs to the hydroxamates, and has a broad range of MMP-
inhibition, which includes MMP 1, 2, 9 and 12. In our experiments, we used 
ilomastat in a dose which equalled the summative dose administered by 
Ferdinandy’s group, demonstrating cardioprotection. We showed that not only 
did ilomastat protect the heart from ischaemia – reperfusion in wild type mice, 
but this protection was independent of an effect the MPTP- ie it occurred in 
mice which were deficient of cyclophilin D. This has not been demonstrated 
previously in vivo. Furthermore, we also showed that inhibition of MMP activity 
did not result in delayed opening of the MPTP, confirming that the protective 
effect was independent of MPTP inhibition.  
The additive benefit of ilomastat to MPTP inhibition is a very attractive clinical 
concept, and raises the possibility of either lone administration (of ilomastat), 
and the potential of co-administration with MPTP blocking agents such as 
cyclosporin A to gain added benefit, which may result in a substantial 
reduction in infarct size, not yet seen, even with cyclosporin A in human 
myocardial infarction. 
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What has not been uncovered by our investigations is the precise mechanism 
by which ilomastat protects the heart. Future investigations will involve the 
measurement of MMP and TIMP levels over the time frame of ischaemia and 
reperfusion, and the time frame involved in the reduction of MMP activity. 
MMPs do appear to be essential for the trigger phase of preconditioning by 
adenosine, bradykinin and opiates (219-221). 
Previous clinical trials have been set up in a variety of clinical disease 
processes (159) including cancer models (161), periodontal disease (200) and 
wound healing (201) to identify the clinical potential of inhibition of matrix 
metalloproteinase activity. The clinical utility of these agents has been limited 
by the side effects of long term administration in clinical trials – primarily due 
to development of the musculoskeletal syndrome.  
In a review of some ten years ago, this very issue was discussed (155), and 
the authors concluded that the likely role of MMP inhibition was as part of 
combination therapy on a long term basis to treat heart failure in the aftermath 
of myocardial infarction. However, on the basis of the data we have obtained, 
there could possibly be a place for MMP inhibition administered as a single 
dose at the time of reperfusion to attenuate lethal reperfusion injury. Single 
dosing could potentially abolish the deleterious effects on the musculo- 
skeletal system which have been the thorn in the side of the MMP inhibitors, 
as this appears to be related to their longer term administration (200).  
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In this chapter we set out to test the hypothesis that administration of a matrix 
metalloproteinase inhibitor at reperfusion would be cardioprotective in a 
manner which was independent of cyclophilin D. 
We have confirmed that there is significant attenuation of myocardial damage 
after ischaemia-reperfusion in cyclophilin D deficient mice in comparison to 
wild type. 
This series of experiments also shows that administration of the matrix 
metalloproteinase inhibitor ilomastat at the time of reperfusion results in 
significant cardioprotection in wild type mice subjected to ischaemia and 
reperfusion. 
We have also confirmed the cardioprotective effect of ischaemic 
preconditioning in wild type mice exposed to ischaemia-reperfusion. 
 
We have demonstrated a significant attenuation in the degree of myocardial 
damage after ischaemia-reperfusion in cyclophilin D deficient mice treated 
with a matrix metalloproteinase inhibitor. 
 
We have shown that when an inhibitor of MMPs was administered to wild type 
mice exposed to ischaemic preconditioning there was no further reduction in 
infarct size than with IPC alone. 
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This data confirms the hypothesis that administration of a matrix 
metalloproteinase inhibitor at the time of reperfusion protects the heart in the 
absence of cyclophilin D. 
As expected from previous published work we found that ilomastat protected 
wild type hearts from ischaemia-reperfusion (154).  
We confirmed previous data from our centre, and others, that IPC also 
confers a cardioprotective effect in wild type mice (experimental data in 
chapter 4 (54, 77, 189, 196, 200, 201)).  
We also found that ischaemic preconditioning (IPC) did not have an additive 
effect to matrix metalloproteinase inhibition in wild type mice subjected to 
ischaemia-reperfusion. This was expected, as published data has 
demonstrated that IPC modifies MMP activity (152,197). Also, if there is a 
conditioning “threshold” then this would be met by one or other method, but 
no added benefit would be derived from application of two differing stimuli- it 
has been shown that application of IPC or pharmacological pore inhibition 
does not reduce infarct size in mice lacking cyclophilin D (54). One 
confounder to this is that in hypercholesterolaemic rats, where there is no 
clear benefit from IPC, cardioprotection could be achieved by administration 
of MMP inhibitors, suggesting that the mode of protection by IPC and MMP 
inhibition differs (154). 
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The finding that ilomastat administration resulted in a significant reduction in 
infarct size in the cyclophilin D deficient mouse would be in keeping with the 
mode of protection achieved by ilomastat being independent of an effect on 
function of the MPTP. This is a novel finding, which challenges previous data 
which to date has suggested it is not possible to protect the heart of the 
cyclophilin D deficient mouse (12,54).  
This data suggests therefore, that there is a non-MPTP mediated pathway to 
cardioprotection, which has the potential for clinical utility in the setting of 
acute myocardial infarction.  
 
Timing of MPTP Opening Using Confocal Laser Microscopy 
 
To investigate its mode of action further ilomastat was administered to 
isolated cardiomyocytes exposed to laser light- triggered reactive oxygen 
species. MPTP opening was not altered in comparison to controls, whereas 
cyclosporin A (used as a positive control) did show delayed MPTP opening 
(data not shown). This suggests that the mode of action of ilomastat is 
independent of an effect on pore function. (The confocal laser experiments 
were carried out by Dr Robert Bell and Dr Sean Davidson, Hatter Institute, 
UCL). 
This data strongly supports that the protective effect of ilomastat is 
independent of MPTP inhibition. However, the mechanism by which it 
achieves cardioprotection is unknown.
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6.10 Suggestions for Future Study 
 
“Late” Administration of Ilomastat 
A further series of experiments could be conducted to assess whether 
administration of ilomastat after the time period when the MPTP is known to 
open (within the first few minutes if reperfusion) would potentially provide 
further confirmatory evidence that this protective process is non- pore 
mediated. However, the proposed non-MPTP pathway may also require 
intervention within the first few minutes of reperfusion, so a result showing no 
protection with “late” administration of ilomastat is not essential in 
demonstrating independence from PTP-related protection. 
 
Signalling mechanisms involved 
The signalling method resulting in the cardioprotection observed with 
ilomastat is unclear. Ilomastat has been shown to inhibit MMP activity, but 
exactly how this results in cardioprotection is not known. Investigation of the 
role of the reperfusion injury salvage kinase (RISK) pathway, which is central 
and upstream to the protection of MPTP inhibition would perhaps reveal a 
possible mechanism of protection. Suggested study would involve use of the 
Western blotting technique to determine whether there was an increase in 
phosphorylation of kinases, such as that found in IPC.  
 
Assay to determine MMP and TIMP levels 
Confirmation of reduction in MMP activity would be essential to guide further 
study into the cardioprotective effect of ilomastat. Thus, measurement of the 
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baseline gelatinase levels (MMP- 2 and 9) would be of value as well as the 
post treatment levels. The effect of ilomastat on tissue inhibitor of 
metalloproteinases (TIMPs) would also be of great interest.  
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Chapter 7  
 
Discussion and Conclusions 
The role of this thesis was to evaluate further the role of the mitochondrial 
permeability transition pore in cardioprotection from ischaemia-reperfusion 
injury.  
The primary focus was to assess whether it is possible to improve 
cardioprotection by a variety of means- increasing the IPC stimulus, improving 
the sub-cellular selectivity of cyclosporin, and finally, by assessing whether 
cyclophilin D is essential in cardioprotection.  
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7.1 Summary of findings 
 
In chapter 4, using an in vivo murine model of ischaemia- reperfusion injury, 
we examined the effect of increasing the IPC stimulus on the infarct size 
sustained in both wild type and cyclophilin D deficient mice.  
We have confirmed previous data which demonstrated that wild type mice 
could be protected by a single 5 minute cycle of IPC.  
Increasing the IPC stimulus to three cycles of 5 minutes IPC and ischaemia- 
reperfusion continued to demonstrate a cardioprotective effect, but this was 
not significantly different to that observed with a single cycle of IPC in wild 
type mice. 
Cyclophilin D deficient mice had a lower observed infarct size in comparison 
to wild type mice which corresponds to literature suggesting that they are in 
an inherently protected state. In this chapter, this was not statistically 
significant, although there was a trend to smaller infarct sizes in CypD knock-
outs. Experiments detailed in chapter 6, however, did confirm a significantly 
smaller infarct size in cyclophilin D deficient animals. 
In cyclophilin D deficient mice there was no reduction in infarct size after 
exposure to a single 5 minute cycle of IPC in comparison to control protocol. 
This is in keeping with published data on this subject. 
In cyclophilin D knockouts, after increasing the IPC stimulus to three cycles of 
5 minutes IPC, there was no statistically significant cardioprotective effect 
observed. However, there was a trend towards protection in this group. 
The statistical methods employed were very rigorous as discussed in chapter 
4. If fewer groups had been compared, it is possible that protection of the 
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cyclophilin D deficient heart may have been demonstrated with three cycles of 
IPC. 
Further experiments to investigate this could potentially compare a smaller 
number of experimental groups, which may improve the statistical ability to 
demonstrate a reduction in infarct size. Alternatively, further increasing the 
number of cycles of preconditioning could be an option. However, due to the 
mechanical limitations of repeatedly snaring and reperfusing the left anterior 
descending artery causing localised trauma and no-reflow, it was felt not to be 
technically possible in this model. 
From the experimental data presented in chapter 4, we can conclude that 
there is a trend towards cardioprotection of the cyclophilin D deficient heart 
with an increase in the IPC stimulus, but in our data this did not reach 
statistical significance. 
In chapter 5, we investigated whether it was possible to enhance the 
cardioprotective effect of cyclosporin A in vivo by targeting the drug at a sub-
cellular level to mitochondria, by using a novel mitochondrial-targeted form of 
cyclosporin A (mtCsA) which was administered at the time of reperfusion.  
Despite previous published data showing very encouraging results in cellular 
models (135), we were unable to demonstrate any protection against 
ischaemia-reperfusion injury in the in vivo setting. 
The potential reasons for this are numerous. In the absence of prior in vivo 
work using the molecule, we were faced with selecting an arbitrary dose for 
administration. We selected three doses, all of which were a fraction of the 
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dose used for conventional cyclosporin A.  This was based on the assumption 
that increased selectivity would mean more active drug would reach the target 
site (ie cyclophilin D). The drug was also difficult to reconstitute- we used the 
same method employed in making cyclosporin A – reconstituting with a 
solution of cremophore and ethanol, and sonicating to aid dissolution.  
Ethanol itself has been shown to be cardioprotective in a number of 
experimental models (224). It is possible that its use as a vehicle may prevent 
demonstration of a protective effect by a therapeutic substance, as the vehicle 
itself would delay MPTP opening. Evidence suggesting that this effect was not 
important is provided by the fact that control infarct sizes were similar to those 
observed in the other chapters with identical durations of ischaemia.  
Later experiments carried out by Dube et al (192) revealed the reason for the 
lack of efficacy- the binding affinity of the mtCsA molecule was dramatically 
reduced by the process used to achieve mitochondrial selectivity. The sterical 
modifications required in order to make the molecule mitochondrial- selective 
caused shielding of the active zinc-binding site preventing it binding to 
cyclophilin as expected. 
The same paper detailed above uses another novel form of mtCsA and 
cellular work has shown that it has improved MPTP inhibition in comparison to 
cyclosporin A, and is biologically active at much lower doses. This could 
potentially have a future in reducing the infarct size after ischaemia- 
reperfusion. 
In vivo work is required to test the true potential of this new form of 
mitochondrial targeted cyclosporin A, which may hold some promise in the 
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treatment of STEMI- but any human use of this drug will be dependent on 
satisfactory pre-clinical data, and safety data from phase I-IV clinical trials, 
which would involve a process lasting years. 
In chapter 6, we investigated the potential role of non-MPTP pathways in 
ischaemia-reperfusion by administering a matrix metalloproteinase inhibitor 
(ilomastat) at the time of reperfusion. This was administered to both wild type 
and mice deficient in cyclophilin D to firstly confirm previous data 
demonstrating its cardioprotective effect (in wild type), and  to ascertain 
whether it was possible to protect the myocardium from ischaemia in mice 
lacking cyclophilin D, a major component of the MPTP.  
These experiments confirmed that wild type mice were protected by ilomastat, 
with a significant reduction in infarct size from 35% to 22% (P=<0.05).  
We also showed that ilomastat administered at the time of reperfusion 
resulted in a significant reduction in infarct size in the cyclophilin D deficient 
mouse. Infarct size was reduced from 21% to 10% by ilomastat (P=<0.05). 
This data would suggest that ilomastat may protect by a method which is not 
dependent on cyclophilin D inhibition.  
To further investigate this theory, isolated wild type cardiomyocytes were 
exposed to laser-light triggered reactive oxygen species and the effects of 
cells treated by ilomastat were compared with those treated with cyclosporin 
A (used as a positive control). The cyclosporin A treated cells had delayed 
pore opening, whereas the ilomastat-treated cardiomyocytes did not, 
indicating that MPTP function is not affected by treatment with ilomastat. 
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This data would suggest that the cardioprotective effect of ilomastat is not 
mediated by inhibition of MPTP function, as MPTP function is attenuated due 
to the congenital absence of cyclophilin D, which is its major constituent. This 
is a new finding- demonstrated in two different experimental models in our 
centre, and suggests that there exists a pathway mediating protection from 
lethal reperfusion injury which is pore independent. This area holds 
substantial potential for further research and pharmacological studies. 
 
We have therefore demonstrated in this thesis that it is possible to protect the 
cyclophilin D deficient heart in vivo. The experiments of chapter 4 which 
showed a non-significant trend to protection with an increase in the IPC 
stimulus suggested, but did not prove, this hypothesis. The experiments in 
chapter 6 showed that there was significant protection of the CypD deficient 
heart subjected to treatment with the matrix metalloproteinase inhibitor 
Ilomastat. The mechanism for protection by Ilomastat has not yet been 
elucidated. However, the confocal microscopy experiments by Bell and 
Davidson which show that Ilomastat does not delay MPTP opening would 
appear to suggest that its protection is not pore-mediated. This raises the 
possibility that there is a pathway to cardioprotection from necrotic cell death 
which is not MPTP dependent. 
Chapter 5 investigated whether it was possible to maintain cardioprotection 
whilst avoiding the deleterious effects of cyclosporin A by targeting the drug to 
its desired site of action in mitochondria and found that the molecule 
investigated did not protect the heart against ischaemia-reperfusion. However, 
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it is possible that mitochondrial-targeting through nanoparticle technology may 
increase the ability of cyclosporin A to protect the heart in future.  
7.2 Potential Clinical Implications 
The reduction in infarct size obtained by administration of the MMP inhibitor 
ilomastat could potentially represent a significant step forward in the 
understanding of lethal reperfusion injury and the processes involved in cell 
salvage. 
There may be significant cardioprotection achieved when administered alone, 
but co-administration of this agent with pore inhibitors, such as cyclosporin A 
could potentially result in an even greater reduction infarct size in comparison 
to cyclosporin alone.  
7.2.1 Adjunct to primary angioplasty 
In the setting of acute STEMI (ST segment elevation myocardial infarction), 
administration of ilomastat, either alone or in combination with the MPTP 
inhibiting effect of cyclosporin A could potentially result in a very large 
reduction in infarct size due to the synergistic actions of pore inhibition and 
MMP inhibition as found in our experimental data. This could potentially be 
large enough to finally translate into the real, measurable clinical benefit, 
which to date has eluded researchers in this field. 
7.2.2 Elective cardiac surgery 
In a similar manner, in the setting of elective high risk cardiac surgery or 
percutaneous coronary intervention, this drug could potentially be 
administered prior to reperfusion, bypass or angioplasty, potentially limiting 
the myocardial damage occurring at that time. As noted above co-
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administration with pore inhibitor (cyclosporin A) could potentially yield a 
superior clinical benefit to lone administration, as ilomastat appears to have 
additive benefit to MPTP inhibition. 
7.3 Limitations and Suggestions for Future Studies 
As the data contained in this thesis relates to a murine model of ischaemia-
reperfusion injury, there are a number of limitations. 
In keeping with the legislation in the Guidance on the Operation of the 
Animals (Scientific Procedures) Act 1986, we have minimised the quantity of 
animals used in each experiment. In the case of the experiments of chapter 4, 
we were unable to answer fully the research question, as to do so would have 
required use of a large number of animals to demonstrate a negative result, 
and we did not feel that this was scientifically or ethically justified. 
The major limitation of use of animal models are that, as found in many 
clinical trials of myocardial infarction that the data obtained may not be directly 
applicable to human patients with multiple co-morbidities. This has been a 
substantial reason for failure of translation into new clinical therapies for 
myocardial infarction to date. 
This thesis did not re-evaluate the novel version of mitochondrial targeted 
cyclosporin A, as this was not available at the end of the study period. It would 
have been helpful to determine if the new method of manufacturing with a 
differing linkage method to the triphenylphosphonium cation, which facilitates 
mitochondrial selectivity, demonstrated cardioprotection in vivo. This molecule 
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could potentially protect the heart at lower doses than those required for 
protection with conventional cyclosporin A.  
Investigating the mechanism of the cardioprotection afforded by matrix 
metalloproteinase inhibition would be a very interesting and essential part of 
the experiments provoked by this research. The finding of enhanced 
cardioprotection above that seen with inhibition of the mitochondrial 
permeability pore prompts a series of experiments. 
Confirmation of a significant reduction in MMP activity in response to 
administration of ilomastat would confirm that MMP reduction is one possible 
mechanism of the cardioprotective effect of ilomastat. 
It would also be useful to assess the effect of MMP inhibition on the signalling 
mechanisms involved in cardioprotection, eg the RISK pathway. 
Additional experiments could include assessment of the effect of MMP 
inhibition on caspase levels and mitochondrial morphology to determine if the 
pathway being inhibited is apoptosis. 
Confirmatory studies in a larger animal model would be desirable, and if 
successful, the ultimate test of ilomastat would be in administration to humans 
being treated for acute myocardial infarction. A useful tandem study would be 
to assess the benefit in co-administration with cyclosporin A in acute 
myocardial infarction, measuring traditional measures of cardiac damage such 
as high sensitivity troponin, brain natriuretic peptide and left ventricular 
function by magnetic resonance imaging, as well as mortality both in the short 
and long term. 
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Appendix 
1.1 Ex vivo data showing cardioprotective effect of increased IPC 
stimulus 
The following data has been reproduced from unpublished work by Andrea 
Carpi, Roberta Menabò, Emy Basso, Paolo Bernardi and Fabio Di Lisa. In this 
work, an ex vivo model of ischaemia- reperfusion has been used. 40 minutes 
of ischaemia was used with a variety of IPC protocols (no IPC, 3 x 5 minutes 
IPC, 5 x 5 minutes IPC), followed by 15 minutes of reperfusion in both C57 
and cyclophilin D deficient mice. The outcome measure was lactate 
dehydrogenase release. The results are demonstrated below. 
 
 
 
 
 
 
 
 
 
 
Heart tissue Coronary effluent 
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The absence of CypD resulted in a significant decrease of LDH release 
induced by post-ischemic reperfusion (23.9±3.7% vs 41±4.7% of total LDH 
content in CypD-/- and WT mice, respectively). As expected the 3 cycle IPC 
protocol resulted in a high degree of protection that however was significantly 
enhanced by CypD ablation (17.2±2% vs 7.7±1.6% in WT and CypD-/-, 
respectively). The increase in IPC protection was decreased when the less 
robust protocol of 1 cycle IPC was applied (19.9±12.1% vs 13.7±4.9 in WT 
and CypD-/-, respectively) and appeared to be rather specific.  = p<0.05  
1.2 
Identification and characterisation of novel inhibitors of the MPTP and 
their efficacy in cardiac infarction.  
Contursi, Ballarini, Fancelli, Carpi, Di Lisa et al have also studied the effects 
of administration of small molecular weight inhibitors of the MPTP (referred to 
as “Congenia Inhibitors”). They studied the effects of administration of these 
agents to purified human liver mitochondria, and measured the calcium 
retention capacity, which is a surrogate marker for MPTP opening.  
The calcium retention capacity of purified liver mitochondria is determined by 
measuring the point at which pulse loaded calcium is released from the 
mitochondria (detected by fluorescence). MPTP inhibition results in a delay in 
release of calcium. 
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Reproduced from Contursi et al (unpublished). The congenia inhibitor is 
referred to as GNX. The above diagram demonstrates that the congenia 
inhibitor has similar effect on calcium retention to cyclosporin A, but also that 
there is an additive effect with cyclosporin A resulting in further delay in 
calcium release from mitochondria. 
 
 
The congenia inhibitor has also been shown to be protective in an ex vivo 
model of ischaemia-reperfusion injury (see overleaf). 
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Reproduced from Contursi et al, (unpublished).  In this ex vivo model, the 
congenia inhibitor reduces release of lactate dehydrogenase, a measure of 
myocardial damage. 
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